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Cancer is a leading cause of death in the world; consequently, an increasing number of 
studies have been dedicated to the improvement of cancer therapy treatments over sev-
eral decades. 
The objective of this thesis is to fabricate anti-cancer liposomal formulation, with a 
novel, improved composition, consisting of lipid vesicles encapsulating anti-cancer drug 
doxorubicin (DOX) and to spectroscopically characterize these liposomes. In addition, 
the internalization process of the drug in cells was studied by using advanced fluores-
cence imaging techniques. 
DOX is used for wide variety of cancer types but its main disadvantage is high toxicity 
for other healthy organs and tissues that can lead to fatal complications. The use of lipo-
somes as carriers of DOX is thus very appealing to counteract this disadvantage and 
protect the healthy tissues from contact with the DOX toxicity. A number of DOX lipo-
somal formulations using active loading methods have been developed. With these 
loading methods large amounts of DOX are encapsulated and lead to the formation of 
dimers, lowering drug activity.  
In this work a carrier system made of Dioctadecyldimethylammonium Bromide (DO-
DAB) and 1-oleoyl-rac-glycerol (Monoolein (MO)) with a ratio of (1:2) is proposed. 
This system has recently been described to have the potential of encapsulating drugs, 
not only at the DODAB enriched bilayer level, but also at the inverted non-lamellar 
MO-enriched phases at the vesicle interior. 
After fabrication the stability of the liposomal system was tested by measuring the size 
and zeta potential of the liposomes.  Four different ‘nano-ruler’ n-(9-anthroyloxy)-
stearic acid (n-AS) probes at 3
rd
, 6
th
, 9
th
 and 12
th
 – carbon positions of an membrane 
inserted lipid chain were used for determination of the nanoscale localization of DOX 
inside the liposome bilayer. These studies revealed that DOX is located closest to the 9-
AS probe, close to the bilayer center. The internalization of the liposomal formulation in 
epidermoid and lung carcinoma cells was analyzed using confocal imaging. It was con-
cluded that the formulation with DOX encapsulated in DODAB:MO (1:2) has more 
controlled drug release compared to the free drug and a commercial formulation, con-
firming the potential of the developed formulation for cancer treatment. 
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1. INTRODUCTION 
Despite thorough research over many decades, cancers still figure amongst the leading 
causes of death. According to the World Health Organization (WHO) in 2012 alone 
there were 14 million new cases and 8.2 million cancer related deaths worldwide 
(World Health Organization 2015). 70% increase in new cancer cases is expected by 
2030.  
Since 1970s doxorubicin (DOX) is used as chemotherapy drug to treat many types of 
cancer, amongst them are: hematological malignancies (for example, leukaemia and 
lymphoma), different types of carcinoma (solid tumours) and soft tissue sarcomas 
(Momparler et al. 1976). The key disadvantage of this anticancer drug is high toxicity to 
other healthy organs and tissues that can lead to fatal complications.  
Novel drug delivery methods using nanocarriers, such as state-of-the-art pH-sensitive 
liposomes loaded with DOX, show favourable results in counteracting with this disad-
vantage and protecting the healthy tissues from contact with the DOX toxicity. The first 
liposomal DOX formulation Doxil
®
 was approved by United States’ Food and Drug 
Administration in 1995 (Barenholz 2012), since then liposomal formulations have been 
profoundly researched. Marlene Lúcio and Elisabete C.D. Real Oliveira from University 
of Minho created the Dioctadecyldimethylammonium Bromide (DODAB) and 1-oleoyl-
rac-glycerol (Monoolein (MO)) - DODAB:MO liposomal formulation, which shows 
advantageous pH-dependent release and drug-loading characteristics, compared to other 
liposomal formulations. Full characterization of the phase behaviour and aggregate 
morphology of DODAB:MO mixtures at different molar ratios have been done 
(Oliveira et al. 2012). The ratio 1:2 was found to be the most stable and with high en-
capsulation efficiency (Van Dijck 2013). DODAB:MO has been successfully investi-
gated for small interfering RNA delivery (Oliveira 2016) and potentiality of encapsulat-
ing drugs, such as DOX, have been researched (da Rocha 2014).  
Currently, there are no studies showing the depth where in the DODAB:MO (1:2) lipo-
some´s lipid bilayer DOX is located.  The location of the drug within the bilayer is im-
portant in liposome characterization. If the drug is more towards the exterior or the inte-
rior of the liposome it could have interesting applications for drug delivery, and, for 
example, may indicate that it is possible to deliver more drug at once without dimeriza-
tion occurring. Furthermore, liposome-cell interaction for the specific liposome and 
cancer cell lines has not been reported.  
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The aim of this master thesis is to for the first time study DODAB:MO(1:2) liposomal 
formulation nanoscale location of DOX within the lipid bilayer and investigate lipo-
some-cell interaction. Thus the objective is to spectroscopically characterize pH-
dependent liposome formulation and, in addition, internalization process of the DO-
DAB:MO (1:2) loaded with DOX in cells should be analyzed by using advanced fluo-
rescence imaging techniques. This study is the continuation of recently published results 
of (Silva et al. 2014) who studied effect of incubation temperature on DODAB:MO 
lipoplex structure. 
In order to reach the aim, DODAB:MO (1:2) liposomes were fabricated using thin lipid 
film hydration method followed by extrusion, and for spectroscopic characterization 
studies n-(9-anthroyloxy)-stearic acid (n-AS) probes and varying concentrations of 
DOX  were added. Liposome size and surface charge were determined by dynamic and 
electrophoretic light scattering, and nanoscale localization of the drug was determined 
by a fluorescence quenching assay. In addition, using Förster resonance energy transfer 
(FRET) analysis the distances between DOX and probe molecules were determined. For 
cellular uptake studies, two different cancer cell lines (A431 and A549) were used. Each 
cell line was exposed to liposomal formulation with varying DOX concentration, to 
commercial liposomal formulation Doxil
®
 and free DOX suspension in water solution. 
Cellular uptake was studied measuring the fluorescence emission signal of DOX using a 
laser scanning confocal microscope. Fixed cell samples, that were fixed after different 
time points of exposure to the drug sample solutions, as well as live cells exposed to the 
DOX-loaded liposomes, and for which time-lapse 3D image series have been recorded, 
were analysed. 
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2. SMART DELIVERY SYSTEMS FOR CANCER 
TREATMENT 
Chemotherapy, and especially, anthracyclines, is a powerful strategy that has been 
widely used for cancer treatment in clinical therapy. Anthracyclines are anti-tumour 
agents (with antibiotic activity) that interfere with enzymes involved in deoxyribonu-
cleic acid (DNA) replication during all phases of the cell cycle (American Cancer 
Society 2015). They are used for a wide range of cancers. DOX is a common anthracy-
cline prescribed for cancer treatment. Smart drug delivery systems show several benefits 
as carriers of anticancer drugs, for example, reduced toxicity of anticancer agents used 
in chemotherapy and achieve the desired therapeutic effect with lower dose, and, possi-
bly, enhanced efficacy. Liposomes are considered one of the best drug delivery systems 
for low molecular weight drugs, imaging agents, peptides, proteins, and nucleic acids 
(Laouini et al. 2012; Lian & Ho 2001).  
2.1 Liposomal delivery systems 
Liposomes, first discovered in United Kingdom in 1961 by A. D. Bangham, are artifi-
cial microscopic spherical-shaped vesicles (Immordino et al. 2006).  Research of lipo-
somes expanded over the last years, broadening their application fields from drug and 
gene delivery to diagnostics, cosmetics, long-lasting immune-contraception to food and 
chemical industry. Ten liposomal and lipid-based formulations have been approved by 
regulatory authorities and many liposomal drugs are in preclinical development or in 
clinical trials (Laouini et al. 2012).  
Liposomes have one or multiple concentric lipid bilayers (lamellas) surrounding an in-
ternal aqueous compartment. Liposomes´ safety and success as carriers for drugs is in 
part due to their chemical and structural resemblance with natural cellular membranes. 
Usually, cell membrane bilayer consists of phospholipids in two monolayers in which 
the non-polar, hydrocarbon chain groups are facing away from the water and face each 
other, while the polar, hydrophilic headgroups of the phospholipid are attracted to the 
water in interior and exterior of the cell (Laouini et al. 2012). This hydrophobic effect is 
further ensured by intermolecular forces like electrostatic interactions, hydrogen bond-
ing, van der Waals and dispersion forces (Laouini et al. 2012). 
Liposome’s membrane can be composed of natural and/or synthetic lipids, amino acid 
surfactants or other materials which have the following properties: biocompatibility, 
biodegradability and they consist of non-immunogenic material. Liposomes’ bilayer 
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structure is unique and it allows using liposomes as carriers for lipophilic as well as 
water-soluble molecules. Hydrophilic substances are incorporated in the interior aque-
ous compartment while lipophilic drugs are mainly trapped within lipid bilayers. Lipo-
some offers protection for both the drug encapsulated and the healthy tissue from the 
harming mutual influence (Lian & Ho 2001). The attractive biological properties, in-
cluding the biocompatibility and biodegradability, of liposomes have been affirmed by 
different authors (Laouini et al. 2012; Lian & Ho 2001).  Amongst other advantages are 
high encapsulation efficiency, and stability against chemical and environmental influ-
ences; target-specific delivery of encapsulated drugs, and sustained drug release. Lipo-
some small size (~50-1000 nm) allows relatively higher intracellular uptake than other 
systems (Laouini et al. 2012).  
If liposomes are intravenously administered most of them tend to accumulate in the 
bone marrow, lymph nodes, spleen, lungs, and liver. Furthermore, solid tumours and 
sites of inflammation and infection have increased blood flow and vascularisation to 
feed the cancer cells which tend to divide extremely fast and need nutrition. This leads 
to increased possibility to accumulate the liposomes close to tumour and inflammation 
sites - the effect is widely known as enhanced permeability effect (EPR).   
Nanoparticles are recognized and removed from the cardiovascular system by the re-
ticuloendothelial system (RES) or the mononuclear phagocyte system before interacting 
with the cell membrane. pH-sensitive liposomes’ size are typically tuned to be smaller 
than 250 nm and thus less recognized by RES while still big enough to cause the fa-
vourable EPR effect. When pH-sensitive liposomes are PEGylated they are able to 
evade RES and to specifically trigger the release of the loaded drugs in response to the 
change of pH in the surrounding environment. The liposomes with prolonged circula-
tion time and RES avoidance property were named by Dr. Frank Martin as “stealthy”, 
which means unseen or unrecognized as foreign particulates by the RES. 
2.1.1 pH-dependent liposomes 
Rapid recognition of conventional liposomes by the cell’s RES mainly in liver and 
spleen leads to short plasma half-lives (time in which liposome loses half of its pharma-
cologic, physiologic, or radiologic activity) (Elron-Gross et al. 2009). Therefore, their 
clinical potential is not fully used. Besides, liposomes enter cells mainly via the endocy-
tosis pathway and eventually reach the lysosome within the cell. In the lysosome, lipo-
somes and their encapsulated drugs or genes are exposed to the risk of being degraded 
by lysosomal enzymes, which will further significantly reduce the drug efficacy (Liu & 
Huang 2013).  
Stimuli-sensitive liposomes are proposed to avoid degradation of loaded drugs in ly-
sosomes and to release their ingredients in one go as a result of destabilization of the 
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liposome membrane caused by specific stimuli (for example, changes of physiological 
pH, tissue specific enzymes, temperature or electrolyte concentration, etc.) (Liu & 
Huang 2013). pH-sensitive liposomes enable the encapsulated drugs to be specifically 
targeted to cancerous tissues (such as primary tumours, metastases, inflammation etc.) 
of the body in which pH varies from the normal physiological value. Tumours and in-
flamed regions are to some extent more acidic with pH of about pH 5.3, when compared 
to normal tissues with pH 7.4 (Liu & Huang 2013). 
pH-sensitive liposomes shall deliver drug or genes into the cell cytoplasm via the endo-
cytosis pathway. Internalization via the endocytosis pathway is stable. Then, liposomes 
are mainly destabilized in the low pH endosomes and are directly released into the cyto-
plasm from there being able to reach nucleus or mitochondria targets. 
2.1.2 DODAB:MO (1:2) liposomes 
The state of the art liposomes investigated in this project are formulations composed of 
DODAB and MO in a 1:2 ratio.  
2.1.2.1 Chemical structure 
DODAB is a monovalent cationic surfactant that forms large unilamellar vesicles  
(LUV’s) in excess water. It consists of a double acyl chain (C18:0) bounded to a qua-
ternary ammonium headgroup. This hydrophilic headgroup part gives the single positive 
charge per molecule, which is screened by the counter-ion bromine (Br
-
). 
DODAB has a gel-to-liquid crystalline phase transition temperature (Tm) of 45 °C (Silva 
et al. 2012). Below Tm the lipid is in a solid-crystalline or ‘gel’ phase, above the Tm it is 
in a liquid-crystalline or ‘fluid’ phase. In the liquid-crystalline phase, the lipids are ca-
pable to diffuse freely within its plane. In this phase lipids are receptive for drugs to be 
encapsulated (Berg 1993). DODAB’s Tm is high when compared with the human body 
temperature (37 °C), meaning that DODAB’s bilayers are rigid at normal body tempera-
ture. Furthermore, DODAB liposomes are highly stable and do not release the drugs 
instantly when administered.  
Other cationic surfactants such as DODAC, where the counter-ion is a chloride (Cl
-
), 
have been researched. However, DODAB forms more densely packed bilayers at the 
headgroup region than DODAC, and it also exhibits lower Tm values and less toxicity 
than DODAC. 
Although the increased rigidity of DODAB liposomes is an advantage regarding the 
stability of the liposomes, it may also result in a more difficult encapsulation of the 
drugs. This limitation can be counteracted by adding a helper lipid with a lower Tm, for 
example, monoolein (MO), cholesterol and dioleoylphosphatidylethanolamine (DOPE), 
which will lower the Tm of the lipid formulation (Silva et al. 2012). 
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MO is a neutral lipid composed by an unsaturated amphiphilic hydrocarbon chain at-
tached to a glycerol backbone by an esther bond. Its amphiphilic molecule nature is due 
to the hydrophilic headgroup and to the hydrophobic chain. MO degrades by esterase 
activity in tissue thus MO is biodegradable. Other interesting characteristics of MO are 
its affordable price, non-toxicity and biocompatibility. 
Specific feature of H2O/MO system is the excess water-phase separation region and 
formation of two inverted bi-continuous cubic phases. As a result MO forms non-
lamellar vesicles with negative curvature. This makes MO an interesting helper lipid 
able to decrease the structural stiffness of DODAB vesicles - lateral mobility of the lipid 
chain is increased and fusion of the liposomes with the cell membrane is improved. 
Tuning MO content in DODAB:MO formulations is important for the formulation de-
velopment for drug delivery purposes. The ratio DODAB:MO (1:2) promotes the for-
mation of lamellar phases of DODAB:MO enclosing a pool of MO inverted non lamel-
lar phases. According to this lipid tuning, these lipid nanocarriers have the advantages 
of a liposome, containing the same lamellar ordered bilayer that confers stability for the 
carrier cargo, but do not have an aqueous filled core. Instead, the vesicle core is filled 
with a sponge-like honeycombed structure rich in MO with internal aqueous channels, 
where the loading of hydrophilic/lipophilic cargos is very much increased. MO has an 
additional advantage to lower the net positive charge of the liposome, which decreases 
transfection-associated cytotoxicity (Silva et al. 2012). 
2.1.2.2 State-of-the-art on DODAB:MO(1:2) 
Research efforts to improve the safety profile of the DOX by encapsulation into various 
types of liposomal formulations have shown reduced cardiotoxicity and better survival 
of the experimental animals compared to the controls receiving free drugs (Laouini et al. 
2012). DODAB:MO liposomal systems have been previously investigated for delivery 
of DNA and bovine serum albumin (Silva et al. 2008; Van Dijck 2013; Oliveira et al. 
2015).  
 
Figure 1. DODAB:MO (1:2) liposome. A- a cryo-TEM image, B- an adapted sche-
matic model. Adapted from (Oliveira et al. 2012) 
In this study, the DODAB:MO (2:1) liposomal formulation for the first time is studied 
in the frame of a nano drug carrier for the well known anti-cancer drug DOX in terms of 
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nanoscale drug localization and cell uptake characterization. The liposomal formulation 
was chosen because of its potential to increase the DOX loading efficiency without risk-
ing dimerization of the drug. The DODAB:MO liposomes have single lipid bilayer 
structure, but MO can be found also in non-lamellar structures inside the core of the 
liposome (Figure 1). The bilayer is mostly composed of DODAB, but with some MO 
lipids randomly dispersed throughout. As MO has a bent shape and is neutrally charged 
and DODAB is positively charged, DODAB and MO form cationic liposomes. DO-
DAB:MO (1:2) liposomal systems are not toxic to cells (Oliveira 2016). 
The net positive charge of DODAB:MO (1:2) formulation is favourable because cell 
membranes usually have slightly negative surface charge. The opposite charges may 
help the binding of the nanocarrier to the cell. Additionally, the neutral MO favours 
drug encapsulation within the liposome. The drug is encapsulated at inverted non-
lamellar MO-enhanced phases inside of the vesicle. DODAB:MO liposomes have shelf 
life of about one month at 4 °C.  
In the current commercial formulations, active loading techniques are used to precipitate 
DOX in the aqueous pool of the liposomes, highly increasing the drug content. This 
active loading mechanism, however, has raised some concerns about DOX dimerization 
and other toxic effects associated with the dimers, besides the smaller efficiency of 
DOX dimers to successfully intercalate within the DNA bases. The development of a 
new liposomal formulation, DODAB:MO liposomes, aims to increase the lipid content 
in comparison to the regular liposomes. Therefore, by possessing a lipid filled core rich 
in MO inverted structures the formulation proposes to increase the amount of DOX that 
can be loaded into the liposome by a passive loading technique, avoiding dimerization 
as well as provide a more stable drug delivery system. High concentration of DOX is 
able to partition in liposomes, the partition coefficient (Kp) at pH 5 of DOX in DO-
DAB:MO (1:2) is reported to be 2818 (da Rocha 2014). The DODAB:MO (1:2) based 
nanocarriers show enhanced release in low pH medium indicating preferential release 
mechanism in cancer tissue (pH 5) compared to blood serum (pH 7.4) (da Rocha 2014). 
To ensure that DODAB:MO (1:2) liposomes can be used as a nanocarrier system for the 
anti–cancer drug DOX, they have to be further characterised. Especially interesting is to 
know, where and how deep in the bilayer DOX is encapsulated, and to understand the 
uptake mechanism by performing in vitro cell studies to follow the time dependent in-
tracellular distribution of  DOX. 
2.2 Doxorubicin (DOX) 
DOX is a widely used, naturally fluorescent anthracycline antibiotic, anticancer drug. 
Although, the mechanism of action of DOX still remains unclear, two major mecha-
nisms of intracellular cytotoxicity of DOX in cancer cells have been proposed:  
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1. Intercalation into DNA leading to the inhibition of DNA replication; 
2. Production of reactive free radicals that results in DNA damage or lipid peroxi-
dation (Thorn et al. 2012). 
 
Figure 2.  Ball-and-stick model of DOX (blue - nitrogen, red - oxygen, white – hy-
drogen, grey – carbon) with surface charge distribution (red- polar zones, blue- 
non-polar zones). Created with software MarvinSketch 16.5.2 
©
. 
The active site of DOX is generally considered to be the nucleus of the cell. At physio-
logical pH, DOX has positive charge, which favours intercalation with DNA by electro-
static binding to the negatively charged phosphate backbone (Drugbank.ca 2013). In 
addition, it inhibits the enzymes necessary for cell replication, leading to cell death. 
However, the lack of cell specificity and therefore risk of organ damage limits the 
maximum dose that can be safely prescribed, lowering the efficacy of the cancer ther-
apy.  
DOX is an amphiphilic molecule consisting of a hydrophobic tetracycline ring con-
nected via a glycosidic bridge and a hydrophilic amino saccharide, the daunosamine 
(Figure 2). This pH-dependent feature allows DOX to be transported either in the inter-
nal aqueous core of liposomes or in its lipid membrane. DOX has three prototropic pKa 
forms. DOX is an amphoteric molecule as the protonatable amino group of the sugar 
moiety (PKa1 = 8.15) gives basic features, while the deprotonation of phenolic rings 
(C11 with pKa2 = 10.16 and C6 with pKa3 = 13.2) give it acid characteristics. 
DOX monomers have a major anti-tumour role while DOX dimers have less or no effi-
cacy (Nakanishi et al. 2001). Dimerization of DOX in high concentrations can occur in 
either a parallel or antiparallel configuration.  
2.2.1 Commercial liposomal formulation – Doxil® 
Doxil
®
 is a PEGylated liposomal formulation encapsulating DOX that was the first 
nanoengineered FDA-approved therapeutic, and is used as an effective cancer treatment 
medication for different types of cancers. Doxil
®
 reduces the cytotoxicity of DOX by 
increasing the specificity and accumulation of DOX within the tumour site (Barenholz 
2012). Nearly all liposomal medicines currently need to be injected intravenously as the 
liposomes will degrade in the digestive tract (Barenholz 2012). Doxil
®
 liposomes are 
excreted from the body after several days, and the possibility of accumulation at sites 
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with a leaky vascular system is increased. Average liposome size in liquid suspension is 
reported to be about 90 nm (Bao et al. 2004). Surface-bound methoxypolyethylene gly-
col molecules covering the phospholipid bilayer, a process known as PEGylation, pro-
tect the liposomes from being detected by the mononuclear phagocyte system. This is a 
passive targeting strategy (Barenholz 2012). 
Several new liposomal formulations have been proposed for the delivery of DOX (Silva 
et al. 2011; Neves Silva et al. 2014; da Rocha 2014). Majority of them uses “active 
loading” methods and a minority that use “passive loading” methods that achieve small 
encapsulation efficiencies of the drug. The “active loading” method allows encapsulat-
ing more DOX in liposomes, but it has the drawback of drug precipitation and forma-
tion of dimers. In case of Doxil
®
, liposomes are loaded with DOX HCl by the ammo-
nium sulphate gradient technique. DODAB:MO liposome formulation (Neves Silva et 
al. 2014), enable increased amount of DOX, that can be loaded into a liposome without 
dimerization. 
2.3 Cell interaction with liposomes 
Cellular uptake studies can provide a better understanding of interaction between devel-
oped liposomes and cells. Based on that, liposomal formulations can be further opti-
mized in order to enhance effectiveness and smart drug delivery. 
Several liposome-cell interaction mechanisms have been reported in literature: 
 Adsorption, release of content; 
 Adsorption, transfer of lipophilic compound; 
 Fusion; 
 Endocytosis (Silva et al. 2012; Ducat et al. 2011; Kamps & Scherphof 2003). 
 
Figure 3 schematically depicts endocytosis of pH-sensitive liposome (Shukla 2016).  
Endocytosis is the most widely accepted cell internalization mechanism for liposomes, 
but it is possible that several pathways occur in parallel. This could be explained by the 
fact that specific cell lines prefer a particular mechanism of internalization but can use 
more than one mechanism. 
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Figure 3. Scheme of the endocytosis pathway of pH-sensitive liposomes. The rele-
vant interaction mechanisms are illustrated: 1 - cellular association of lipo-
somes; 2 - liposome in early endosomes; 3 - destabilization of endosome mem-
brane and release of contents by pH-sensitive liposomes or 4 - lysosomal degra-
dation; 5 - therapeutic agent fuses into cytoplasm; 6 - transport of therapeutic 
agent to the target; 7 – exocytosis, adapted from: (Shukla 2016). 
Mechanisms of liposome-cell interaction depend on the size, type and the composition 
of the liposomal formulation but also on the cell type and cell-cycle phase. Due to this, 
it is beneficial to study the cellular uptake of a specific liposome on more than one cell 
line. In this thesis, A431 (epidermoid carcinoma) and A549 (lung cancer) (Figure 4) 
human cell lines were used to assess the cellular uptake of DODAB:MO encapsulating 
DOX. 
 
Figure 4. Bright-field microscopy images taken with a Nikon Ti, Eclipse microscope 
of the cell cultures used for confocal imaging: A549 (A) and A431 (B) showing 
cells without introduction of liposomes. 
Untreated A549 cells are triangle shaped with wide and flattened cell morphology as 
can be observed in the bright-field microscope images taken to confirm proper cell 
growth during cell culturing (Figure 4 A). 
A431 cells are derived from 85 years old female patient with epidermoid carcinoma. 
This cell line has high expression of epidermal growth factor receptor (EGF) (ATCC 
A B 
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n.d.). Doubling time for this cell line is between 25 and 30 hours (ATCC 2014). If A431 
cells are stimulated with EGF it induces rapid tyrosine phosphorylation of intracellular 
signalling proteins, which control cell growth, proliferation and apoptosis (Graness et 
al. 2000). It has been reported that EGF reduces the resistance to DOX in A431 cell line 
(Kwok & Sutherland 1991). A431 cells are irregularly shaped, some individual cells 
tend to spread in spindle-like shapes but when colonies are formed cell shape changes to 
more compact irregular shape and they tend to grow in several layers, as can be seen in 
the bright-field microscope images taken during the cell culturing assay (Figure 4 B). 
In vitro cell culture system experiments provide the opportunity to study liposome-cell 
interactions, by, for example, confocal laser scanning microscopy, fluorescence lifetime 
imaging microscopy and others. In addition, co-localization studies can be done of la-
belled particle components and dyes, or antibodies that recognize cell organelles or 
molecules playing a role in the process. 
2.4 Suitable liposome characterization techniques 
One of the most commonly used techniques to characterize liposomes are fluorescence-
based techniques and their main advantage is possibility to monitor complexes' behav-
iour under physiological conditions (Madeira et al. 2011). The dynamic and electropho-
retic light scattering (DLS and ELS) techniques are used for liposome size distribution 
determination and surface charge (potential zeta) determination, and a fluorescence 
quenching method for nanoscale localization of the drug inside the liposome formula-
tion. FRET analysis allows to measure distances between fluorescent probes with sensi-
tivities below 10 nm. In addition, microscopy methods such as atomic force microscopy 
and transmission electron microscopy can be used to assess macroscopic structure of 
liposomes (Madeira et al., 2011). For cellular uptake studies, laser scanning confocal 
microscopy has advantages of high resolution and ability to obtain information in three 
dimensions (3D). 
2.4.1 Dynamic Light Scattering (DLS) 
DLS is a well-known technique for measuring the size and size distribution of mole-
cules and particles in suspension. Brownian motion is the unsystematic movement of 
particles, which is the result of collisions with the solvent molecules that surround them. 
The speed of these particle movements is used to determine particle size (Malvern In-
struments 2000; Malvern Instruments 2013) 
The speed of Brownian motion depends on the particle size, solvent viscosity and tem-
perature. The bigger the particle is, the slower it moves, the higher the temperature is, 
the more rapid Brownian motion becomes. The laser light passing through the sample is 
scattered by the diffusing particles. The mean velocity of the Brownian motion relates 
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to the translational diffusion coefficient, which can be used to determine a particle size 
using the Stokes-Einstein equation (Malvern Instruments 2000; Malvern Instruments 
2013). 
2.4.2 Electrophoretic Light Scattering (ELS) 
ELS can be used to measure the ζ-potential of the particles and it is used to characterize 
the stability of colloidal dispersions. The ζ-potential indicates the degree of electrostatic 
repulsion between neighbouring, similarly charged particles in dispersion. For small 
particles, high ζ-potential indicates stability – particles in the suspension will resist ag-
gregation. When the potential is relatively small, the absence of charge repulsion may 
cause particle’s flocculation. Particles with ζ-potentials higher than +30 mV or lower 
than -30 mV are normally considered stable. 
 
Figure 5. Diagram showing the ionic concentration and potential difference as a 
function of distance from the charged surface of a particle, adapted from 
(Malvern Instruments 2013) 
Ions that are in the liquid surrounding the suspended particles are attracted to their sur-
face if they have an opposite charge. The net charge at the particle surface determines 
the distribution of ions in the surrounding interfacial region, resulting in an increased 
concentration of counter-ions close to the surface. Liquid surrounding the particle can 
be described as electric double layer: closer to the particle, called the Stern layer, where 
the ion binding strength is strong, and further, a diffuse layer, where ions are less 
strongly bonded (Figure 5). There is a theoretical boundary in the diffuse layer where 
the ions and particles are stable. These ions, which are within the boundary, move with 
the particle. But any ions beyond the boundary are independent from the particle. This 
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boundary is called the slipping plane and the potential at slipping plane is the ζ-
potential. 
ELS experiments consist on applying a potential difference to a capillary, where the 
sample flows. Then the charged particles move to the poles of opposite charge and the 
velocity of the particles is measured using Laser Doppler Velocimetry, from which elec-
trophoretic mobility is obtained. From the electrophoretic mobility and by application of 
the Henry equation it is possible to determine the ζ-potential of the particles (Malvern 
Instruments 2000). 
2.4.3 Nanoscale drug localization 
The target site of DOX is the cell nucleus where it is presumed that the drug binds to 
nucleic acids by specific intercalation (Drugbank.ca 2013). Therefore, DOX-loaded 
liposomes have to interact first with enzymes and receptors at cell membrane level be-
fore delivering its content to the nucleus. Thus, the concentration and location of the 
drug in the liposomal bilayer is a relevant parameter describing its pharmacologic and 
toxic effects. Elucidating the drug location/concentration at the lipid nanocarrier could 
contribute to optimize formulations with the ability to provide a controlled drug release 
to extend the therapeutic duration. 
 
Figure 6. Structure of DODAX (where X is counter ion) lipid, the AS-lipid with AS-
dye attachment sites. Created with software MarvinSketch 16.5.2
©
. 
There are two types of methods to determine drugs’ location in the membrane: direct 
and indirect.  Direct methods include determination of localization by techniques like 
X-ray and neutron diffraction, nuclear magnetic resonance, infrared spectroscopy, and 
others (Mason et al. 1991). Indirect methods require a foreign compound that is usually 
a fluorescent probe, often referred to as molecular ‘ruler’. The fluorescent probes used 
in this study are lipid molecules with fluorescent groups placed on varying specific lo-
14 
  
cations of the acyl chain (see Figure 6). The fluorescent lipid probes are then inserted 
within the other lipid components of the liposomal formulation loaded with the drug. If 
a chosen property of the probes is altered, it is possible that these changes can be related 
to the localization of the drug. 
For example, if the molecular location of a probe within membranes is known with cer-
tainty, the deactivation of the probe fluorescence (also known as fluorescence quench-
ing) induced by a drug can be used to reveal the location of the drug inside the mem-
brane.   
For experiments in this thesis, probes with fluorescent groups on the 3
rd
, 6
th
, 9
th
 and 12
th
 
carbon the acyl chain were chosen. The n-AS probes are inserted within the lipid com-
ponents of DODAB:MO (1:2) vesicles and their lipid chains are aligned with the vari-
ous carbon atoms along the carbon chain of DODAB (see Figure 6). The interactions 
between the fluorescent probe and DOX were studied using drug concentration-
dependent spectroscopic quenching assays, that can be used to determine the static and 
dynamic Stern-Volmer constants. The most strongly quenched dye indicates the loca-
tion, which is closest to the drug. The different optical spectroscopy methods used are 
described below.  
2.4.3.1 Steady-state fluorescence quenching 
Quenching can result from a variety of processes that decrease the fluorescence inten-
sity.  
In order to determine the amount of quenching, correction of the absorbance using the 
ratio of intensities of the steady state emission at the peak of each sample is necessary. 
The emission spectra allow to find the maximum fluorescence intensity values, which 
are then used to calculate quenching.  
Absorbance inner filter correction is made using the Equation 1: 
            
       
       
 
  
  
 ,                                                  (1) 
where A0 is the absorbance value of the system without quencher at chosen wavelength 
and At is the absorbance value of the system with increasing concentrations of quencher 
at chosen wavelength. Fluorescence emission is corrected by the use of Equation 2: 
               
  
  
 ,                                                  (2) 
where If is maximum intensity value of the system without quencher and It is maximum 
intensity value of the system with increasing concentrations of quencher at chosen 
wavelength. One or more quenching mechanisms can occur in a system depending on 
its properties. Collisional or dynamic quenching is due to collisions between quenching 
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agents and fluorophores. The dynamic quenching molecule provides a non-radiative 
route for loss of the excited state energy and return to ground state. In static quenching 
the quenching agent forms a non-fluorescent complex with the quenching agent before 
the excitation occurs. The fluorophore and quencher have to be in contact for static and 
dynamic quenching (Lakowicz 2006b). 
It is expected that the closer the DOX and the probes are physically, the stronger the 
quenching and therefore the larger decrease in steady-state fluorescence and/or lifetime 
(Lakowicz 2006b) .  
Static and dynamic quenching can be distinguished by fluorescence lifetime measure-
ments (which require instruments capable of time resolutions in the nanosecond range), 
and if the quenching process has a dynamic nature an equivalent decrease in fluores-
cence emission intensity and lifetime will occur: 
  
 
 
  
 
  ,                                                                   (3) 
where I0, I and τ0, τ are the measured fluorescence intensities and fluorescence lifetimes 
of the fluorophore in the absence and presence of the concentration of the quencher.  
The effective concentration of the quencher in the lipid membrane [Q]m can be calcu-
lated using equation: 
     
     
              
 ,                                                 (4) 
where Kp is partition coefficient of the drug, Qt concentration of the drug added (in M) 
and Vm is the volume of lipid in membrane (Lakowicz 2006a). 
In case of collisional quenching the graphical representation of the values of fluores-
cence intensity (
  
 
  ) or lifetime (
  
 
  ) as a function of [Q]m of the drug shows lin-
ear behaviour with a slope that corresponds to the Stern-Volmer constant (KSV) that in 
this case is also called dynamic constant (KD).  
In a static quenching mechanism, fluorophore and drug form a complex that is non-
fluorescent and fluorescence that is detected corresponds to the fraction of non-
complexed fluorophores. Thus, in a static quenching, the fluorophores that are bound 
with the drug are undisturbed and the lifetime of the excited state remains constant: 
  
 
                                                                   (5) 
Linear Stern-Volmer plots do not prove that dynamic quenching of fluorescence has 
happened. Static quenching can result in linear plot as well. With fluorescence lifetime 
measurements it is possible to determine, which quenching process occurrs. 
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Non-linear Stern-Volmer plots with a downward curvature towards the x-axis may indi-
cate that there is a mixture of fluorophores that are not exposed to the quencher together 
with fluorophores that are more accessible to the quencher. This negative deviation to 
Stern-Volmer linear plots is common in proteins that may contain several populations of 
intrinsic fluorophores. Indeed, proteins can contain tryptophan, tyrosin and phenyla-
lanine residues that act as fluorophores and are positioned in distinct environments. 
Stern-Volmer plots for these proteins frequently curve downward, reflecting the 
quenching of the accessible fluorophore, only.  
Non-linear Stern-Volmer plots with an upward curvature can occur when the extension 
of quenching is high and can be due to uneven distribution of either the quencher and/or 
the fluorophore. Combined static and dynamic quenching and the sphere-of-action 
model can explain positive deviations from linear Stern-Volmer plots: 
1. Combined static and dynamic quenching 
In many cases the fluorophore can be quenched both by collisions and by complex-
formation with the same quencher, traduced by the following equation: 
  
 
                       
 
,                                 (6) 
where KD and KS are respectively the Stern-Volmer constants for dynamic and static 
quenching.  
2. Sphere-of-action model 
Positive deviations from linearity in the Stern-Volmer plot are also frequently observed 
when the extent of quenching is large, and it happens when the quencher is close to the 
fluorophore at the moment of excitation. The modified form of the Stern-Volmer equa-
tion that describes this situation is: 
  
 
           
       ,                                              (7) 
where Vapp is the apparent volume of the sphere adjacent to the fluorophore where there 
is higher probability to find the quencher at the time of excitation. This volume can be 
calculated by: 
             
  
       
 ,                                              (8) 
where Vsphere is the additive volume of the quencher and the fluorophore. 
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2.4.3.2 Time-Correlated Single Photon Counting (TCSPC) 
To determine fluorescence quenching of the AS probes in the presence of DOX, fluo-
rescence lifetime spectroscopy, specifically time correlated single photon counting 
(TCSPC), can be used. With this method a deeper understanding of the liposomal for-
mulation can be obtained.  
TCSPC is a technique used for measuring the fluorescence decay times in ranges start-
ing from picoseconds and above. It is intended for samples with exceptionally small 
concentrations of fluorophores. High sensitivity and accuracy with picosecond time 
resolution are the advantages of TCSPC. 
The principle of TCSPC is based on the detection of single photons and the measure-
ment of their arrival times with respect to a reference signal. Samples are excited using 
a pulsed light source to achieve data collection of the arrival times of the individual 
photons over many excitation cycles. Then decay curves are constructed from many 
individual time measurements (Wahl 2014b).  
 
Figure 7. Adapted experimental set-up for fluorescence decay measurements with 
TCSPC. Adapted from (Wahl 2014a). 
Figure 7 shows a schematic set-up for fluorescence lifetime measurements with TCSPC. 
The picosecond diode laser is running on its internal clock. The driver box is separate 
from the actual laser head, which is attached with a flexible lead. The light pulses of 
typically 50 ps are directed at the sample cuvette through appropriate optics. A neutral 
density filter is used to attenuate the light levels to maintain single photon statistics at 
the detector.  
Upon excitation, the fluorescent sample emits light at a longer wavelength than that of 
the excitation light. The fluorescence light is filtered out against scattered excitation 
light by means of an optical cut-off filter. A polarizer is placed in front of the photomul-
tiplier tube (PMT) detector and oriented at the magic angle 54.7 degrees, with respect to 
the linear polarization of the laser excitation beam. The light then is detected and ampli-
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fied PMT. The electrical signal obtained from the detector is fed to the TCSPC electron-
ics. The laser driver also provides the electric synchronization signal (SYNC) needed 
for the photon arrival time measurement (Wahl 2014a). Figure 8 illustrates how time 
differences between the excitation and the photon detection are measured by electronics 
that act like a stopwatch (Wahl 2014a). The histogram of photon arrival times with re-
spect to laser excitation pulses are formed over multiple cycles. 
 
Figure 8. Measurement principle of start-stop times in time-resolved fluorescence 
measurement with TCSPC, diagram adapted from (Wahl 2014a). 
TCSPC is statistical method and high repetition pulsed laser sources are required in or-
der to accumulate sufficient amount of photon events for certain precision. The prob-
ability of registering more than single photon per cycle needs to be low. With TCSPC 
only the first photon within one laser repetition period is observed. Consequently, sev-
eral photons cannot be detected if operated at too high intensities. Therefore the inten-
sity has to be low such that typically in many cycles no photon is registered (Wahl 
2014b). The detection rate used in the described measurments in this thesis was 1 pho-
ton per 1000 000 excitation pulses. The time is measured between the excitation pulse 
and the observed photon and stored in a histogram. 
The difference in the amount of time it takes for an absorbed photon to be re-emitted 
gives useful information about the sample. Fluorescence lifetime of the n-AS probes 
could be dependent on their interactions with the DOX, as DOX is capable of taking up 
some of the energy from the probe, leading to a faster photon re-emission from the 
probe. Fluorescence dynamics typically can be characterized by a multi-exponential 
decay: 
          
      
             (9) 
where Ai denotes the amplitude and τi the decay times of the M exponential components 
of the fluorescence decay. 
The instrument response function (IRF) is measured once before all TCSPC measure-
ments were performed to summarize TCSPC system’s overall timing precision. Usually 
one of the weakest timing components in TCSPC system is the detector. The accuracy 
of timing is limited by the conversion from a photon to an electrical pulse by the detec-
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tor. Another weak component of the system is the excitation source - it can broaden the 
IRF curve. Thus, a short 50 ps pulsed laser is used. 
Analysis of the fluorescence decay data includes appropriate mathematical fitting and 
deconvolution in order to account for the IRF and to calculate fluorescence decay for 
each sample.  
2.4.4 Förster Resonance Energy Transfer (FRET) 
Quenching requires molecular contact between the fluorophore and quencher. The 
amount of quenching is sensitive to molecular factors that affect rate and probability of 
contact due to short interaction distance. FRET on the other hand occurs up to distances 
of about 10 nm between FRET partners, which are fluorescent molecules with a suited 
spectral overlap and relative molecular orientation. 
FRET describes mechanisms in which a decrease of the intensity of fluorescence of one 
species acting as donor is due to transference of the energy to an acceptor. In collisional 
quenching the emission intensity of initially excited molecule decreases regardless the 
acceptor being fluorescent or non-fluorescent. Comparison of FRET and quenching 
gives better understanding of the nature of both processes. 
In quenching mechanisms, DOX will act as the acceptor and the probe will act as the 
donor, allowing energy to be transferred between the probe and DOX. While DOX itself 
is a fluorescent molecule, the spectra of the fluorescent markers on the n-AS-probes and 
DOX only allow the transfer of energy from the AS probes to the DOX, as the AS 
probes absorb higher energy photons than DOX. It is expected, that the closer the DOX 
and the probes are physically, the more efficient is the FRET process. 
In the FRET mechanism the rate of energy transfer depends upon i) the extent of spec-
tral overlap of the emission spectrum of the donor (AS probes) with the absorption 
spectrum of the acceptor (DOX), ii) the quantum yield of the donor, iii) the relative ori-
entation of the donor and acceptor transition dipoles, and iv) the distance between the 
donor and acceptor molecules. The distance dependence of FRET allows measurement 
of the distances between donors and acceptors. 
The transfer efficiency (E) is the fraction of photons absorbed by the donor that are 
transferred to the acceptor and is given by: 
  
  
 
  
       
,                                                            (10) 
where rD-A is the distance between donor and acceptor, R0 is the Förster distance, which 
is the distance at which FRET is 50% efficient. From Equation (11) it is possible to cal-
culate the distance between donor and acceptor: 
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 .                                                    (11) 
E is typically measured using the relative fluorescence intensity of the donor, in the ab-
sence (ID) and presence of the acceptor (IDA): 
    
   
  
.                                                     (12) 
The Förster distance can be calculated by: 
          
           
   ,                                         (13) 
where k
2
 is a factor describing the relative orientation in space between the transition 
dipoles of the donor and acceptor, n is the refractive index of the medium, QD is the 
quantum yield of the donor in the absence of acceptor, and J(λ) is the overlap integral in 
the region of the donor emission and acceptor absorbance spectra (with the wavelength 
expressed in nanometers).  
Often the observation of FRET is enough to identify binding events, even without cal-
culation of the D–A distance, as FRET is limited to short distances of about 10 nm. 
From comparison of the distance for FRET with the size of the molecules, one can see 
that FRET is a through-space interaction.  
2.5 Cellular uptake study techniques 
For cellular uptake studies, fluorescence microscopy techniques were considered be-
cause of DOX’s fluorescence properties. DOX has wide excitation (450-550 nm) and 
emission (525-650 nm) spectra (see results from the spectroscopic studies presented in 
Figure 16 and 22). 
Confocal microscopy has several advantages over conventional optical microscopy 
methods: depth of field is shallow, out-of-focus light is eliminated and it allows to opti-
cally section thick specimens (larger than 2 micrometers). Imaging of both fixed and 
living cells is possible. In addition, it is a method that can be adapted to investigate a 
broad range of systems by varying the excitation or detection wavelength range and 
fluorescent labels (Dailey 2016). 
2.5.1 Confocal laser scanning microscopy 
Confocal microscopy is a specialized technique of light microscopy and is a commonly 
used in cellular uptake studies. Either autofluorescent or samples stained with fluores-
cent markers are required in order to use this technique. 
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Figure 9. Confocal principle based set-up geometry. The scheme shows effective 
blocking of out-of-focus emission by a pinhole that is placed in front of the de-
tector and matched to let the fluorescence signal pass that originates from the 
focal volume, only.  Adapted from (Fujimoto & Brezinsky 2003). 
Laser scanning confocal microscope (LSCM) designs are centred around upright or in-
verted optical microscopes. A laser system is used as a light source to excite fluoropho-
res in the sample, signal information is delivered to a detector (photomultiplier tube or 
avalanche diode) and processed by a computer.  
The principle of confocal microscopy is presented in Figure 9. Coherent excitation light 
emitted from a laser system passes through a pinhole aperture that is in conjugate plane 
with a focus point on the specimen and with a second pinhole aperture that is situated in 
front of a detector. Light is directed onto the sample of interest in a specific focal plane 
by a dichromatic mirror. The fluorescence emitted from the specimen in the same focal 
plane passes back through the dichromatic mirror and is focused onto the pinhole aper-
ture. This pinhole allows the light originating from the focus to pass to the detector, 
while rejecting the majority of the light from out-of-focus planes. This way, the signal-
to-noise ratio for the features of interest is increased (Fujimoto & Brezinsky 2003). To 
use this improved signal-to-noise ratio for high-contrast imaging, a laser scanning sys-
tem is implemented into a confocal microscope setup.  
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Figure 10. Principle of z-stack image acquisition. After each 2D scan of the 
excitation laser in the xy plane, the sample is moved in z direction. This section-
ing allows obtaining 3D images from objects (here a sphere), and can be used to 
investigate single biological cells. 
The image is built up on a pixel-by-pixel basis using the scanning mechanism. The 
scanning principle is represented in Figure 10: A focused light beam is scanned across a 
defined area in a raster pattern by two oscillating mirrors. One of the mirrors is used to 
move the beam from left to right across lateral x axis, while other translates it in y direc-
tion. After scan of x axis beam is moved to starting position and shifted along y axis. 
When information across x-y axis is collected, the position along the z-axis is changed 
and the process is repeated for a defined thickness. 
The properties of visible light set limitations to the achievable resolution in confocal 
microscopy. Wavelength, properties of sample and restrictions of microscope optics 
result in the maximum resolution of about 200 nm. Thus, the minimum distance by 
which two objects can be detected from each other is 200 nm (Fujimoto & Brezinsky 
2003). The size of liposomes is around 100 nm. Therefore, the precise structural infor-
mation about one vesicle cannot be obtained by confocal microscopy but the accumula-
tion of the fluorescent anti-cancer drug DOX around or inside the cells, which typically 
have diameters of around 10 to 30 m can be studied. 
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3. RESEARCH METHODOLOGY AND MATERI-
ALS 
3.1 Liposome sample preparation 
For spectroscopic characterization studies DODAB:MO (1:2) liposome samples were 
prepared containing 3-AS, 6-AS, 9-AS and 12- AS probes and 6 varying concentrations 
of DOX. And for cell internalization studies DODAB:MO (1:2) (DOX@DODAB:MO) 
liposome samples were prepared containing DOX in concentrations of 5 µM and 40 
µM. 
3.1.1 DODAB:MO (1:2) liposomes 
Stock solutions of DODAB and MO (20 mM) were prepared by dissolving the lipids in 
ethanol.  117 µL of DODAB and 233 µL of MO stock ethanolic solutions were added to 
a glass tube and solvent was dried under a nitrogen stream with a constantly rotating 
motion to form a lipid film. Lipid films were hydrated with 7 mL ultrapure water. 
Film/water solution was warmed up above the lipid mixture Tm (60 ºC). A cycle of one 
minute of incubation in a warm water bath at 60 °C and one minute vigorous vortexing 
was repeated for 20 minutes until the whole lipid film was removed from the glass walls 
and the multilamellar vesicles had been formed.  
Subsequently, extrusion process of the vesicles followed using a Northern Lipids Lipex 
Extruder and Nuclepore Track-Etch Membrane filters. The extrusion process uses air 
pressure to apply force to a liquid sample, pushing the sample through a filter with 
pores of the desired size and ensuring the particles in the sample are all uniform. The 
liposomes were extruded to ensure uniform size of about 100 nm. That was achieved by 
extruding the liposomes containing the necessary probe 5 times with a 400 nm filter, 5 
times with a 200 nm filter and 10 times with a 100 nm filter. Extrusion protocol for li-
posomes for cell internalization studies was following: 2 times with a 400 nm filter, 2 
times with a 200 nm filter and 10 times with a 100 nm filter.   
The samples were stored in a fridge at a temperature of 6 °C until further analysis was 
performed. 
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3.1.2 n-AS@DODAB:MO 
For spectroscopic characterization studies DODAB:MO (1:2) lipid films with probes 
were made by pipetting ethanolic stock solutions: 117 µL of 20 mM DODAB, 233 µL 
of  20 mM MO and 7 µL of 10 µM of n-AS (3-AS, 6-AS, 9-AS or 12-AS) probe into 
aluminium foil-covered glass tubes. Aluminium foil was used to avoid bleaching of the 
light-sensitive probes. 
After collecting ingredients in desired ratio a drying process to form lipid films was 
performed. Then lipid films were hydrated with 7 mL ultrapure water. Film/water solu-
tion was warmed up above the Tm (60 ºC). A cycle of one minute of incubation in a 
warm water bath at 60 °C and one minute vigorous vortexing was repeated for 20 min-
utes until the whole lipid film was removed from the glass container and the multilamel-
lar vesicles had been formed. Subsequently, the vesicles were extruded to achieve the 
desired size and homogeneity (described in Section 3.1.1). 
3.1.3 DOX@DODAB:MO 
After the extrusion process, the liposomes were loaded with DOX. Depending on de-
sired experiment with or without n-AS probe and varying concentrations of DOX.  
For quenching studies n-AS labelled DODAB:MO(1:2) liposomes were combined with 
DOX at concentrations ranging from 0 μM to 100 μM (0 μM, 20 μM, 40 μM, 60 μM, 80 
μM, 100 μM). The samples were then incubated in a 37 °C water bath for 60 minutes to 
allow incorporation of the drug into the liposomes.  
For cell uptake studies DODAB:MO(1:2) liposomes without n-AS probes were loaded 
with 5 μM and 40 μM DOX. Samples´ incubation in a 37 °C water bath for 60 minutes 
followed to allow incorporation of the drug into the liposomes. After incubation lipo-
somes were diluted 1:10 in warm (37 °C) Dulbecco's Modified Eagle Medium 
(DMEM). 
3.2 Experimental setup for liposomal characterization studies 
For liposomal characterization the following methods were used: DLS, ζ-potential ex-
periment, fluorescence quenching assay, and FRET analysis. 
Temperature of 40 °C for all measurements was chosen to be at liquid-crystalline phase 
for the liposomal formulation and above phase transition. 
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3.2.1 Dynamic Light Scattering (DLS) 
A volume of 1 mL of DODAB:MO (1:2) sample was placed in a 3 mL disposable poly-
styrene cuvette. The DLS instrument Malvern Zetasizer Nano ZS particle analyser was 
used to measure the mean diameter, its respective standard deviation and the polydis-
persity index (PdI) (Malvern Instruments 2013). 5 runs were performed with parameters 
presented in Table 1. 
Table 1. Parameters used for DLS particle size determination 
Material 
Refractive index  
Absorption 
Polystyrene latex 
1.590  
0.01 
Dispersant  
Temperature  
Viscosity  
Refractive index 
Water 
°C 
0.8872cP  
1.330 
Dispersant viscosity is used as 
sample viscosity  
 
Temperature  
Equilibration time 
25.0 
60 seconds 
Cell type Disposable sizing cuvette 
Angle of detection  
Measurement angle 
 
170° 
Measurement  
Number of runs  
Run duration  
Number of measurements  
Delay between measurements 
 
5 
80 seconds 
1 
0 
Positioning method  
Automatic attenuation selection  
Analysis model 
Seek for optimum position  
Yes 
General purpose (normal resolution) 
 
The PdI is dimensionless and scaled number that is calculated using the cumulants 
analysis. It is related to the peak width of the size distribution graph and shows if meas-
ured sample suspension is mono- or polydisperse. According to Malvern, samples with 
PdI values between 0.05 (highly monodisperse) and 0.7 (broad size distribution) are 
suitable for the DLS technique (Malvern Instruments 2000).  
For soft materials (such as liposomes) it is unlikely to reach these values. In this particu-
lar case, where a combination of two lipids is used, it is even more difficult to reach a 
very low PdI. However, values of lower than 0.2 were considered as acceptable for a 
homogeneous size distribution. 
For particle size measurement Malvern Zetasizer Nano ZS gives the result as an inten-
sity particle size distribution (PSD) and these results are shown in this thesis. However, 
the number distribution was also considered to see if one or several intensity popula-
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tions with distinct sizes are present in the sample solution. By the analysis of the parti-
cle size histogram it is possible to elucidate the number and relative percentage of each 
population.  
3.2.2 Electrophoretic Light Scattering (ELS) 
For ELS experiments, a clear disposable folded capillary zeta cell was filled with 1mL 
of sample and placed in a Malvern Zetasizer Nano ZS analyser. Measurement of 5 runs 
was performed, the parameters used are shown in Table 2. The ζ-potential obtained 
gives information about the liposome surface charge, which cannot be measured di-
rectly. The liposome surface charge determines the tendency of the nanoparticles to 
aggregate, furthermore it allows to estimate the formulation’s shelf stability.  
Table 2. Parameters used to measure the zeta potential 
Material 
Refractive index  
Absorption 
Polystyrene latex 
1.590  
0.01 
Dispersant  
Temperature  
Viscosity  
Refractive index 
Dielectric constant 
Water 
25°C 
0.8872cP  
1.330 
78.5 
F(Ka) selection  
F(Ka) value 
Dispersant viscosity is used as sample viscosity  
Smoluchowski 
1.50 
Temperature  
Equilibration time 
25.0 
60 seconds 
Cell type DTS1060C – Clear disposable zeta cell 
Measurement  
Number of runs  
Number of measurements  
Delay between measurements 
 
5 
1 
0 seconds 
Automatic voltage selection  
Automatic attenuation selection  
Analysis model 
Yes 
Yes 
Auto 
3.3 Nanoscale drug localization studies 
For nanoscale drug localization studies fluorescence steady state emission, absorption 
and fluorescence lifetime spectra were recorded for n-AS labelled DODAB:MO(1:2) 
liposomes containing DOX in varying concentrations. The experimental parameters and 
used set-ups are described in the following sections.  
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3.3.1 Steady-state fluorescence spectroscopy 
The steady state spectroscopy measurements were performed on a Horiba Scientific 
FluoroMax-4 spectrofluorometer. The cuvettes with volume of 1 mL of each sample 
were placed in the spectrofluorometer. Samples analysed were DODAB:MO (1:2) lipo-
some samples labelled with one n-AS probe (where n is 3, 6, 9 or 12) and varying DOX 
concentrations 0 μM, 20 μM, 40 μM, 60 μM, 80 μM and 100 μM (Figure 17).  
The chosen experiment type was spectral acquisition. The excitation wavelength was set 
to 379.00 nm and the emission spectra recorded was from 385.00 to 700.00 nm, with 
increment of 1 nm. Integration time per spectrum was 0.1 s. Front entrance and exit slits 
were set to 2.00 nm slitwidth. The grating had a line density 1200 l/mm. Before starting 
each acquisition a 5 minutes waiting period was set for temperature stabilization. Emis-
sion spectra were recorded once for all 24 samples. 
3.3.2 Ultraviolet-visible spectrophotometry 
The UV-VIS measurements were performed on a Perkin Elmer Lambda 950 UV-VIS 
spectrometer. UV-visible absorbance of each sample was measured between 300 nm 
and 450 nm. To reduce the signal-to-noise ratio, the scan speed was set to ‘slow’ and 
the slit width was set to 2.0 nm.  
Before measuring the samples, absorbance spectrum of the solvent (MilliQ) water was 
recorded with the same settings. This was done for background correction purposes. 
Samples analysed were DODAB:MO (1:2) liposome samples labelled with one n-AS 
probe and varying DOX concentrations 0 μM, 20 μM, 40 μM, 60 μM, 80 μM and 100 
μM (Figure 18). 
3.3.3 Fluorescence Lifetime Spectroscopy 
Fluorescence lifetime spectroscopy was performed using a ChronosBH spectrometer 
from ISS Inc. The measurements were performed for liposomal DODAB:MO (1:2) 
samples with 3-AS, 6-AS, 9-AS and 12-AS probes and 6 different DOX concentrations. 
Each measurement was repeated 5 times. 
In this thesis ISS ChronosBH fluorescence lifetime spectrometer with Hamamatsu pico-
second light pulser PLP-10 exciting at 379 nm wavelength with maximal 363 mW aver-
age laser power and 50 ps pulse duration was used at a repetition rate of 10 MHz.  
A Semrock OD 0.03 filter was placed in front of the sample and a Semrock BP 435/40 
filter was placed in front of the detector to only allow light of 415 to 455 nm to reach 
the detector. As DOX is excited at 480 nm and emits around 590 nm, the filter blocks 
all fluorescence from DOX and only detects photons from the fluorescence of the AS 
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probes. The broadband polarizer in the detection path was set to 54.7 degrees, or the 
magic angle, and each measurement was taken with 20s acquisition time. The laser po-
sition was adjusted to achieve maximum intensity and to ensure that there was no re-
flection occurring that could re-excite the sample and cause incorrect results. The detec-
tor was a PMT from Hamamatsu (H7422-40). Each sample was measured in a 2 mm 
glass cuvette. The IRF was measured a 2 mm cuvette filled with MilliQ water, and the 
Bandpass filter was removed, to let the scattered laser light pass to the detector. 
3.4 Förster Resonance Energy Transfer (FRET) 
Full fluorescence emission spectra recorded with an excitation wavelength of 379 nm 
and a detection range from 385.00 to 700.00 nm in a Horiba Scientific FluoroMax-4 
spectrofluorometer were considered for the analysis of FRET between n-AS probes and 
DOX in the various DODAB:MO (1:2) liposomal formulations. The experimental setup 
described in Section 3.3.2 was used. 
3.5 Cell samples 
Fixed A431 and A549 cell samples were prepared for experiments, additionally A431 
cell samples were prepared for live cell imaging. 
3.5.1 Cell culture assay 
Human carcinoma cell lines A431 and A549 cells were provided by Prof. Andreia Go-
mes from University of Minho (Braga, Portugal). 
A431 (epidermal carcinoma cell line) and A549 (lung carcinoma cell line) cells were 
grown in 75-cm
2 
flasks (BD Falcon, Franklin Lakes, NJ) with 12 mL of Dulbecco’s 
Modified Eagle’s Medium (DMEM) with 4.5 g/L glucose (Gibco® USA) supplemented 
with 10% Fetal Bovine Serum (FBS) (Gibco
®
 USA),  and 1% strep/pen (Penicillin 
(10,000 IU/mL), streptomycin (10,000 µg/mL)), which will be further referred to as 
“cell culture medium” (Gibco® USA). Cell handling was done under laminar flow hood 
and samples were kept in an incubator at 37°C with atmospheric CO2 concentration of 
5%.  
Subculturing was done respecting the American Type Culture Collection (ATCC) rec-
ommendations for both cell lines. Before plating, cells were washed with 5 mL of 1X 
Phosphate-Buffered Saline (PBS) (Sigma-Aldrich, USA) to remove all traces of serum 
that contains trypsin inhibitor.   When PBS was removed, 2 mL of 0.25% trypsin EDTA 
(Gibco
®
 USA) solution was added and cells were incubated in 37°C for 5 minutes. 
When cells were well detached 3 mL of cell culture medium was added and aspirated by 
gentle pipetting.  
29 
  
Then cells were counted using a Newbauer hemocytometer after being diluted 1:1 in 
Trypan Blue counting solution to exclude dead cells, which stain blue. The number of 
cells per mL of cell suspension was calculated knowing the volume of the counted area 
and the dilution factor.  
For new culture vessels in 75-cm
2
 flasks aliquots of 250 000 cells of the cell suspension 
were added to cell culture medium with total volume of 12 mL. Cells were passaged 
every 7 days and medium was changed every 2-3 days. 
3.5.2 Fixed cell samples 
For cell uptake studies A431 and A549 cells were plated at a density of 100,000 
cells/mL in an ibidi 8 well µ-slide (ibidi, Martinsried, Germany) one day prior to imag-
ing. 200 µL of the 1x105 concentration of cells were added to each well. The bottom of 
the µ-slide is glass coverslip no. 1.5H- suitable for microscopy. After incubating for 24 
hours in a µ-dish, the cell culture medium was removed from each well and was re-
placed with 200 µL of either 5 µM free DOX, 5 µM DOX@DODAB:MO, 40 µM 
DOX@DODAB:MO, all in cell culture medium, or diluted (1:80) commercial lipo-
somal formulation Doxil
®
. It was ensured that suspension added to cells contained less 
than 10% of water as higher water content might induce cell death. A control sample of 
cells left without suspension containing the drug was prepared in one of the wells. At 
different time points (1, 2, 4 and 6 hours) after introduction of different suspensions 
containing DOX, these solutions were removed and cells were washed with PBS. When 
PBS was removed, 200 µL of a 4% Paraformaldehyde (PFA) (Sigma-Aldrich, USA) 
solution in PBS was added for 20 minutes, then PFA was removed  washed two times 
with PBS and 50 µL (2 drops) of VECTASHIELD® (Vector Labs, Burlingame, USA) 
mounting medium was added.   
3.5.3 Live cell samples 
For live or living cell experiments the A431 cells were incubated for 24 hours to allow 
cells to adhere and grow till confocal imaging was performed. For visualization of DOX 
uptake in live A431 cells, a nucleus staining fluorescent stain Hoechst 33342 (1:2000, 
molecular probes, Life Technologies, Eugene, USA) was used with incubation time 10 
minutes. 
After incubation and staining cells were gently transferred to the stage top incubator 
system (okolab) in the LSCM where a temperature of 37°C and 5% CO2 environment 
was maintained. When the LSCM system was set and ready for experiment medium 
was removed before adding 200 µL of 5 µM or 40 µM DOX@DODAB:MO in cell cul-
ture medium. When solution containing DOX was added live cell experiment started.  
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3.6 Cell uptake studies of liposomes 
Cell uptake studies for fixed and live A431 and A549 cells were done using confocal 
laser scanning microscopy. 
3.6.1 Confocal laser scanning microscopy 
Confocal microscopy was performed with a Zeiss LSM 780 confocal microscope (Carl 
Zeiss Microimaging GmbH, Jena, Germany). For live cell imaging, okolab incubator 
with temperature and CO2 control was utilized. ZEN 2009 software (Carl Zeiss Microi-
maging GmbH) was used for image acquisition and Fiji/ImageJ software (U. S. Na-
tional Institutes of Health, Bethesda, Maryland, USA) for image processing and 3D ren-
dering.  
For fixed cell uptake studies a 40x times objective (EC PlanNeoFluar 40x/1.3 NA Oil 
immersion, Zeiss) was used. For live cell imaging a higher magnification of 63x (Plan 
Apo 63x/1.4 NA oil immersion, Zeiss) was chosen. Live individual cells were selected 
for a time-dependent observation of the interaction of a cell with the anti-cancer drug 
DOX loaded DODAM:MO liposomes. 
Each sample was imaged simultaneously with both the confocal and transmission mode. 
The transmission images are used to follow the cell shape and location changes, that 
allow deducting the cell cycle state. The confocal images are used to determine the loca-
tion of the DOX within the cells. 353.55µm*353.55µm images with 512 x 512 pixels 
were acquired in the x, y plane. The z-stacks were measured moving the sample using a 
piezostage to move along the varying heights (25-50 µm) of the z-axis (with approxi-
mately 1 µm thick slices). Total number of slices was 25-50 slices. The z-stacks were 
measured at a variety of time points that were fixed after the incubation with DOX con-
taining solutions (1, 2, 4 and 6 hours). Confocal images at varying z-heights were taken 
and combined to create 3D images of the cells. Acquisition time per pixel was 7.7 s and 
488 nm laser intensity used was 0.7. 
For the detection of DOX fluorescence a 488 nm laser was used for excitation and a 
band pass filter with transmission between 531 and 689 nm was placed in front of the 
detector. The fluorescence of the nuclear stain Hoechst 33342 was excited with 405 nm 
laser and a bandpass filter with transmission between 410-491 nm was placed in the 
epifluorescence detection channel.    
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4. DEVELOPMENT OF A FITTING LIFETIME 
ANALYSIS ALGORITHM 
Fluorescence lifetimes were determined using the TCSPC technique. Two different fit-
ting algorithms were examined in order to find the most appropriate one for measured 
data: commercial software Vinci Analysis by ISS for which several drawbacks were 
identified for the analysis of large sets of fluorescence lifetime curves and a new im-
plementation of a fluorescence lifetime analysis tool that was developed in the frame of 
this thesis using Matlab software. Fitting algorithms were tested for data from DO-
DAB:MO+9AS samples with different DOX concentrations.  
4.1 Vinci Analysis by ISS 
The principle of data analysis in the Vinci analysis software is to compare a model with 
the acquired data using a Levenberg-Marquardt algorithm as the minimization routine 
for the χ2 -function. The model with the lowest value for the χ2 -function is chosen for 
the system (ISS inc. 2015). According to ISS, Levenberg-Marquardt algorithm (LMA) 
was chosen because of its speed and stability (ISS inc. 2012). 
 
Figure 11. Example of multi-exponential fitting with  Vinci Analysis by ISS for 
DODAB:MO+9AS+20 µM DOX first iteration data 
LMA is a numeric minimization algorithm that solves non-linear least squares prob-
lems. These problems arise usually in least squares curve fitting. Initial guess for the 
parameters is needed to start the minimization. Levenberg-Marquardt curve-fitting 
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method is a combination of two minimization methods: the gradient descent and the 
Gauss-Newton method. Usually, a standard guess can be made even if it is far from fi-
nal minimum, but in more complex cases the algorithm converges only if the initial 
guess is already close to the final solution (Gavin 2015). Vinci allows data analysis of 
decay times with more complicated models of up to 4 components. It is possible to ana-
lyse each component assuming a lifetime distribution (Planck, Uniform, Gaussian, Lor-
entzian). 
There are several drawbacks, when using the Vinci Analysis by ISS, firstly, only limited 
information about commercial software’s actual algorithm is available, therefore it can 
be classified as ‘black box’ analysis. Secondly, only one dataset at a time can be ana-
lysed. And, lastly, software needs manual input of initial decay times and desired time 
range by two clicks of mouse in plot- nearly impossible to repeat it for each dataset with 
the same precision. In addition, author observed inconsistencies in outputs when the 
fitting was repeated for the same sample several times. The reports from Vinci Analysis 
can be exported in MS Word or PDF format thus are not ready for further analysis. 
All measured data was processed with Vinci Analysis by ISS to obtain lifetime values, 
Figure 11 shows a TCSPC data set taken for 20 µM DOX@DODAB:MO labelled with 
the 9AS probe, the fitted multiexponential curve, as well as the IRF data. 
4.2 Developed Matlab algorithm  
A new fluorescence lifetime analysis tool was implemented using Matlab. Nonlinear 
least-squares solver lsqcurvefit was the basis of this function. It finds coefficients for 
given equation (Equation 9) with given input data and the observed output, where xdata 
and ydata are matrices or vectors, and the function is a matrix-valued or vector-valued 
function.  
This function was mainly chosen because coefficients can have lower and upper bounds 
while other functions do not. Rather than compute the sum of squares, lsqcurvefit re-
quires the user-defined function to compute the vector-valued function. Developed algo-
rithm is available in appendix A. 
The fit function gave very good results that were compatible with those acquired with 
Vinci Analysis by ISS. The example of fit can be seen in Figure 12. The results from 
both methods are discussed below. 
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Figure 12. TCSPC curve of the 9-AS probe inserted into a 20m 
DOX@DODAB:MO liposome at 40 C shown together with the measured in-
strument response function (IRF) and the fit function using a two exponential fit 
model and the developed Matlab algorithm for analysis. 
For DODAB:MO liposomal formulations with varying DOX concentrations, the fluo-
rescence decay measurements show steeper decay curves for higher DOX concentra-
tions. The fit accuracy allows identifying these fluorescence lifetime differences, which 
indicate that a lifetime quenching process occurs (Figure 13).  
 
Figure 13. DOX concentration-dependent fitted TCSPC data taken on  9-AS 
probes inserted into DODAB:MO liposomal formulations (developed Matlab al-
gorithm was used) 
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4.3 Comparison of available fitting methods 
As discussed above, two data processing methods were tested - commercial software 
ISS Vinci and Matlab code developed in this thesis. Figure 14 (A-D) show the mean 
fluorescence lifetime results determined for the same data sets with the different fit al-
gorithms (all values are also given in Appendix B).  The fluorescence lifetimes of the n- 
AS probes in DODAB:MO at various DOX concentrations determined using the Vinci 
software vary between 7.60 – 10.69 ns, while the fit with Matlab leads to lower values 
ranging between x and 6.90 - 8.74 ns. 
Haldar et al. report  <τ> values of 5.72, 8.14, 10.64, 10.88 ns for 2-AS, 6-AS, 9-AS and 
12-AS probes respectively in 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) mem-
branes (Haldar et al. 2012).  The differences found between the obtained experimental 
values and the values reported could be explained by different chemical composition of 
DODAB:MO (1:2) and DOPC membranes.  
 
Figure 14. Comparison of fluorescence lifetime fit results for DOX concentra-
tion-dependent data series taken on the different n-AS probes labelling the DO-
DAB:MO liposomal formulations. ISS Vinci software and Matlab analysis algo-
rithm were used and standard deviations are indicated. Data are shown for A: 
3-AS; B: 6-AS;C: 9-AS and D:12-AS labelled liposomes, respectively. 
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Absolute values obtained with the two techniques are slightly different and differ 
maximally by 2 ns, while the deviation in all cases is to shorter lifetimes in case of the 
Matlab implemented algorithm. Values calculated with Matlab code are constantly 
smaller than those from ISS, but as it can be seen in Figure 14 A-D standard deviations 
were extremely small for lifetime values acquired with Matlab. χ2 values are reported in 
Appendix B and do not deviate from 1 more than 5%. For further analysis lifetime val-
ues acquired with Matlab was used. 
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5. RESULTS 
5.1 Liposomal characterization  
DLS and ELS were used to determine the size and surface charge of DODAB:MO (1:2) 
liposomal formulations. 
5.1.1 Liposome size  
The size and PdI of the DODAB:MO (1:2) liposomes without DOX were measured 
immediately after their extrusion. The mean size for the sample plus the standard devia-
tion and PdI are shown in Table 3. 
Table 3.  The z-average diameters (nm), polydispersity index values and zeta po-
tential mean values ( mV) obtained from measurements of DODAB:MO (1:2) li-
posomes 
 z-Average Diameter 
(nm) 
Polydispersity 
Index (PdI) 
Zeta Potential 
Mean Values 
(mV) 
DODAB:MO (1:2) 118.9 ± 0.5 0.161 ± 0.01 +50.4 ± 9.5 
 
The particle size distribution shows one single peak that corresponds to only one size 
population (Figure 15). 
 
Figure 15. DLS-obtained size distribution of DODAB:MO (1:2) liposomes in 
water 
A small particle size of ~100 nm was desired. The average diameter measured is 118.9 
nm. The liposomes have an average PdI of 0.161. According to Malvern Instruments 
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user manual (2013), if the PdI is below 0.2, it can be concluded that the liposomes in the 
suspension have a monodisperse size distribution. 
5.1.2 Liposome zeta potential 
The mean ζ-potential for each sample plus the standard deviation is shown in Table 3. 
DODAB:MO (1:2) liposomes hydrated with only ultrapure water have a mean ζ-
potential of +50.4 mV at a mean pH value ± standard deviation of 5.5±0.3, which is 
consistent with other reported values for the same type of liposomes (Almeida 2009). It 
means that produced liposomes can be considered stable as their ζ-potential is larger 
than +30 mV. This positive surface charge is advantageous both in terms of shelf stabil-
ity, providing repulsion between the liposomes, and in terms of membrane cell adhesion 
as the positive charges will have higher propensity to interact with slightly negatively 
charged cellular membranes.  
5.1.3 Nanoscale localization of the drug 
Measured fluorescence emission and absorption as well as lifetime data were processed 
and analysed in contemplation of gaining knowledge about nanoscale localization of 
DOX in DODAB:MO (1:2) liposome. 
5.1.3.1 Spectroscopic analysis of n-AS probes inserted into DODAB:MO(1:2) 
liposomes loaded with various concentrations of DOX  
Fluorescence emission spectra were measured for 3 AS, 6 AS, 9 AS and 12 AS labelled 
DODAB:MO(1:2) samples with varying concentrations of DOX 0, 20, 40, 60, 80 and 
100 μM. Excitation wavelength was 379 nm. The data was processed as described in 
Appendix C. 
The typical emission spectra of fluorescence quenching DODAB:MO (1:2) liposomes 
with different quencher concentrations are shown in Figure 16 A-D for the 3-AS, 6-AS, 
9-AS and 12-AS probes, respectively, where it is possible to observe that the drug was 
able to decrease the fluorescence intensity of the fluorescence probe. Furthermore the 
maxima of the longer wavelength absorption band and fluorescence maxima of the 
fluorophore do not change in the presence of quencher. These factors ruled out the pos-
sibility of dynamic or collisional quenching process, however only the lifetime analysis 
can definitely confirm the quenching process. 
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Figure 16. Steady state fluorescence emission spectra taken from 3-AS-, 6-AS-, 
9-AS- and 12-AS- labelled DODAB:MO liposomes containing varying DOX 
concentrations. Besides the emission peak of the n-AS labels peaking around 
450 nm, also DOX emission with two bands at 650 and 580 nm is observed. Ex-
citation wavelength was 379 nm. 
In addition, absorption spectra of all samples were recorded for all samples and used for 
correction of the inner filter effect due to absorbance of the light when the samples are 
excited. The absorbance spectra are shown in Figure 17 (A to D) for the 3-AS, 6-AS, 9-
AS and 12-AS probes respectively. The peak absorbance values for each sample at 385 
nm are used to correct the inner filter effect using Equation (1) and (2), and values are 
given in Appendix D. The absorbance seemingly rises as the concentration of DOX in-
creases. The distances between absorbance spectra of n-AS labelled DODAB:MO(1:2) 
containing varying concentrations of DOX are equal, with exception of two curves (6-
AS labelled DODAB:MO(1:2) with 100 μM DOX and 12-AS labelled DO-
DAB:MO(1:2) with 40 μM DOX). The differences might have arisen due to pipetting 
error. 
As the drug partitions inside the liposomes, the effective concentration [Q]m, (deter-
mined using Equation 4) was used to determine the Stern-Volmer constant and therefore 
[DOX]m values are also used in the Stern-Volmer plots. 
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Figure 17. Absorbance spectra taken from 3, 6, 9 and 12-AS labelled DO-
DAB:MO (1:2) liposomes containing varying DOX concentrations shown in 
A,B, C and D, respectively. For correcting the inner filter effect the peak at 
around 385 nm was analysed. 
The plots in Figure 18 show the steady-state Stern-Volmer plots for the fluorescence 
emission uncorrected (dashed line) and corrected for the inner filter effect (bold line) for 
all the samples of DODAB-MO (1:2) labelled liposomes with increasing DOX concen-
trations. For the various n-AS probes the Stern-Volmer plots present linear behaviour 
with significantly different slopes indicating different quenching efficiencies of the 
probes by the quencher (DOX). It is also visible that neglecting absorption correction of 
the inner filter effect here leads to smaller Stern-Volmer constants. 
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Figure 18. Steady-state Stern Volmer plots. Relative fluorescence intensity 
changes (Io/I) measured at the fluorescence peak maximum located at 485 nm  
(---) and as corrected for inner filter effect using the steady state absorption 
data (___) for 3, 6, 9, and 12-AS labelled DODAB:MO (1:2) liposomes in de-
pendence of encapsulated anti-cancer drug DOX. The concentration of DOX is 
given as the effective drug concentration inside the DODAB:MO(1:2) lipid 
membrane, considering the known partition coefficient of DOX in DODAB:MO. 
Figure 20 shows the dynamic Stern-Volmer constant differences for the different AS 
probes - small decrease of the fluorescence lifetimes in presence of DOX is observed for 
3-AS, 6-AS, 9-AS and 12-AS labelled DODAB:MO(1:2).  Steepest slope for the rela-
tive fluorescence lifetime, thus highest quenching, was observed for the 6-AS probe. 
 
Figure 19. Dynamic Stern-Volmer plots. Relative average lifetime changes for 
all n-AS probes inserted into DODAB:MO(1:2) liposomes of varying concentra-
tions of encapsulated DOX. 
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5.1.3.2 Determination of Stern-Volmer constants 
To determine KSV, the membrane effective concentration of the quencher in the lipid 
membrane [Q]m was calculated using Equation (4). Stern-Volmer constants were ob-
tained from the corrected relative fluorescence steady state emission values I0/I*Fcorr 
plotted as a function of [Q]m and Stern-Volmer constant was determined from the slope 
of the linear fit (Figure 20). The dynamic constant KD was determined from linear fits of 
drug concentration dependent fluorescence lifetime results (Figure 19, 20).  
 
Figure 20. Combined inner filter corrected steady state and dynamic Stern-
Volmer plot used to determine the Stern-Volmer constant KSV, the static KS and 
dynamic KD quenching constant. The concentration of DOX is given as the effec-
tive drug concentration inside the DODAB:MO(1:2) lipid membrane, consider-
ing the known partition coefficient of DOX in DODAB:MO. The TCSPC data 
was fitted using a bi-exponential model, and a weighted average of the lifetime 
components are used to represents the fit results. 
All results are summarized in Table 4 which presents the determined values of KSV, Ks 
and KD values, with Ks= KSV - KD.  
Table 4. Stern-Volmer constant 
DOX Ksv (
 M‐1) KD (
 M‐1) Ks (
 M‐1) 
3 AS 10,6 ± 3,15 0,9 ± 0,3 9,7± 3 
6 AS 14,4 ± 3,19 1,7 ± 0,3 12.7 ± 3 
9 AS 21,8 ± 3,35 1,3 ± 0,3 20,5 ± 3 
12 AS 17,8 ± 2,59 0,7 ± 0,3 17,1 ± 2,5 
 
The bimolecular quenching constant Kq leads to better comparability in case the reporter 
dyes have different fluorescence lifetimes in absence of a quencher. As this is the case 
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for the different n-AS probes it is beneficial to analyse the bimolecular quenching con-
stants (Kq): 
   
   
  
  ,                                                         (14) 
where    is the fluorescence lifetime of the n-AS probe in DODAB:MO (1:2) liposomes 
that was experimentally measured in the absence of quencher.  
The determined Stern-Volmer constants Ksv, measured fluorescence lifetime of n-AS 
probes in DODAB:MO liposomes and in absence of the quencher τ0 and from these 
values derived bimolecular quenching constants Kq are summarized in Table 5.  9-AS 
probe showed the highest Kq value followed by 12-AS, 6-AS and 3-AS probes. 
Table 5. Stern-Volmer and bimolecular quenching constants of n-AS probes 
Probe Ksv, M
-1 τ0, ns Kq, M
-1s-1 
3 AS 10,6 6,90  1,54 *109 
6 AS 14,4 6,14  2,35 *109 
9 AS 21,8 7,33  2,97 *109 
12 AS 17,8 8,74  2,04 *109 
 
Kq assesses the quenching and indicates the accessibility of the fluorophores to the 
quencher (Lakowicz 2006a). Therefore, the analysis of the Kq values (Table 5) indicates 
that 9-AS is the most efficient quencher of the DOX followed by 6- and 12-AS. Diffu-
sion-controlled quenching in homogeneous solvents typically results in values of Kq~ 
1*10
10
M
-1
s
-1 
(Lakowicz 2006a). The smaller Kq values around 1,5 *10
9 
to 3 *10
9 
are in 
agreement with the reported values found for fluorophores bound to macromolecules 
(Lakowicz 2006a) and can result from the fact of the fluorophore being immobilised in 
the lipid membranes. 
5.1.4 Förster Resonance Energy Transfer (FRET) analysis 
FRET analysis was based on measured steady state fluorescence emission data, where 
one can see that with increased concentration of DOX in n-AS labelled DO-
DAB:MO(1:2) system, the intensity of n-AS peak (around 440 nm) decreases (Figure 
16 A-D), and simultaneously the peak intensity of a DOX emission peak around 600 nm 
increases with increased DOX concentration. Thus, the hypothesis can be stated that the 
system contains FRET donor-acceptor pair where n-AS probe acts as donor and DOX as 
acceptor. Figure 21 shows relative changes of fluorescence emission peaks at 440 nm 
and 600 nm as function of acceptor (DOX) concentration for each n-AS probe. The 
highest relative decrease in intensity values at 440 nm (donor) peak (Figure 21 dashed 
lines) is observed for the 9-AS labelled DODAB:MO system, followed by 12-AS, 6-AS 
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and finally 3-AS systems. An interesting trend appears when acceptor (DOX) peak of 
the system at 600 nm is analysed. The intensity at this peak increases as DOX concen-
tration is increased. The relative changes (Figure 21 bold lines) Ia/Id show that the least 
increase in acceptor peak is for 9-AS labelled DODAB:MO system followed by 12-AS, 
6-AS and finally 3-AS. Thus, even though the system with 9-AS probe has the strongest 
decrease of emission intensity at the donor peak, it also is the system with least increase 
of emission intensity at the acceptor peak. 
 
Figure 21. FRET observation between n-AS donor and DOX acceptor mole-
cules in DOX concentration-dependent fluorescence emission spectra taken from 
DODAB:MO liposomal formulations. The relative changes of the fluorescence 
emission peak at 440 nm, associated with the n-AS emission  (I/I0) (donor peak 
quenching) and the relative change of intensity of the acceptor peak at 600 nm 
Ia divided by the intensity Id of the n-AS probe at the considered DOX concen-
tration (acceptor peak rise) are shown for the different n- AS probes. 
For the calculation of the distance between donor (D) and acceptor (A) molecules Equa-
tion 10 was used. Transfer efficiency E was calculated using the relative fluorescence 
intensity (Equation 12). 
In order to calculate the D–A distance it is necessary to know R0 (Equation 13), which 
in turn depends upon κ2, n, QD, and J(λ). These values must be known to calculate the 
distance. The refractive index (n) is 1.35 and a random orientation between D and A is 
assumed which leads to k
2
=2/3. 
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Figure 22. The overlap of the 3-AS labelled DODAB:MO(1:2) emission spec-
trum with the absorption spectrum of the 100 μM DOX in water.  
The overlap integral J(λ) was evaluated for each n-AS – DOX (D–A) pair. The larger 
the overlap of the emission spectrum of the donor with the absorption spectrum of the 
acceptor, the higher is the value of R0. J(λ) was evaluated using a|e - UV-Vis-IR Spec-
tral Software from Fluortools.com. First, the acceptor molar absorption spectra was re-
calculated using the extinction coefficient ε. Extinction coefficient for DOX 
εDox=10410 M
-1
cm
-1
 at λ=481nm was obtained from literature (Tian et al. 2003). Then 
DOX absorption value at peak (λ=481nm) A481 was selected from the measured data 
and multiplication coefficient was calculated to obtain the desired extinction coefficient 
spectrum: 
  
    
    
 
     
      
                                              (14) 
When DOX absorption extinction coefficient spectrum is in units of M
-1
cm
-1
 the spec-
tral overlap integrals between acceptor absorption and donor emission spectra can be 
calculated. DOX absorption extinction coefficient spectrum and 3-AS, 6-AS, 9-AS and 
12-AS emission spectra were plotted in the a|e graph window and spectral overlap inte-
gral was calculated (see Figure 22). 
Quantum yield values for the n-AS donor probes (QD) have been reported as inserted 
into a variety of systems, for example, in sonicated dispersions of dipalmitoyl phos-
phatidyleholine (Thulborn et al. 1979), in cytosol haemoglobin (Eisinger & Flores 
1982), in Triton X-100 micelles and in sodium dodecyl sulphate (SDS) micelles 
(Berberan-Santos & Prieto 1987) summarized in (Table 6). The quantum yield values in 
sonicated dispersions of dipalmitoyl phosphatidyleholine, in cytosol haemoglobin and 
in Triton X-100 micelles are similar, whereas values in SDS micelles differ. 
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Since QD is used as the sixth root in the calculation of R0, small errors in QD do not have 
a large effect on R0, the quantum yields obtained in the chemically most comparable 
environment for the n-AS probes therefor shall be selected for the further FRET analy-
sis.  
Table 6. Quantum yield values of the donors (n-AS probes) in different systems 
Probe In sonicated dis-
persions of di-
palmitoyl phos-
phatidyleholine  
(Thulborn et al. 
1979) 
In cytosol hemo-
globin (Eisinger & 
Flores 1982) 
In Triton X-100 
micelles (Berberan-
Santos & Prieto 
1987) 
In SDS micelles 
(Berberan-Santos & 
Prieto 1987) 
2 AS 0.35 0.33 0.14 0.07 
3AS - - 0.18 0.07 
6 AS 0.41 0.4 0.31 0.08 
9 AS 0.4 0.44 0.41 0.12 
12 AS 0.47 0.47 0.55 0.15 
 
Figure 23 shows the chemical structures of the studied n-AS molecular environments. 
One can see that dipalmitoyl phosphatidyleholine molecule (Figure 23 D) has two car-
bon chains and a headgroup. This structure is the most similar to DODAB’s, therefore 
quantum yield values in sonicated dispersions of dipalmitoyl phosphatidyleholine mi-
celles were used for the calculation of the D-A distance.  
 
Figure 23. Chemical structures of systems used elsewhere in combination with 
n-AS probes. A: dipalmitoyl phosphatidyleholine (Wikimedia 2007b); B: haemo-
globin (Wikimedia 2016); C: Triton X-100 (Wikimedia 2007a); D: SDS 
(Wikimedia 2008) 
The set of Equations 13, 14 and 15 is used for the determination of E, R0 and subse-
quently for the determination of the distance rD-A and under consideration of the SDS 
lifetime values (Table 6), a measured DOX absorption spectrum (see Figure 22) and the 
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measured steady state fluorescence emission spectra measured in 20M DOX@ DO-
DAB:MO (1:2) liposomal solutions for the different probes shown in (Figure 16 A-D, 
orange curves). This way calculated D-A distances are displayed in Table 7, along the 
determined spectral overlaps J(λ) and the FRET efficiency parameter E.  
The shortest distance, 24.8 Å, is between 9-AS and DOX molecules. Then 3-AS (25.2 
Å) and 12-AS (25.7 Å) distances follow, the longest is between 6-AS and DOX mole-
cules (27.7 Å). 
Table 7. Determined J(λ) and calculated E and D-A distances for n-AS and DOX 
FRET pair 
Probe J(λ), 
nm4/(M*cm) 
E rD-A, Å 
3AS 2.7E+14 0.87 25.2 
6 AS 2.96E+14 0.83 27.7 
9 AS 2.93E+14 0.90 24.8 
12 AS 3.17E+14 0.90 25.7 
Qd value used obtained from sonicated dispersions of dipalmitoyl phosphatidyleholine (Thulborn et al. 1979) 
5.2 In Vitro studies of cancer cell uptake  
The cellular uptake of the liposomal formulation was evaluated using two cancer cell 
lines: A431 and A549. Comparison was made between DOX@DODAB:MO and free 
DOX and DOX@DODAB:MO and the commercial DOX formulation Doxil
®
. 
5.2.1 Comparison of DOX@DODAB:MO versus free DOX up-
take  
Both cancer cell lines, A431 cells (epidermoid carcinoma) and A549 cells (lung carci-
noma), were exposed to the liposomal formulation DOX@DODAB:MO (1:2) and to 
free DOX solutions with overall identical 5 µM DOX concentrations. The samples were 
fixed after 1, 2, 4 and 6 hours of exposition to the DOX containing solutions. The DOX 
fluorescence intensity distribution was measured in A431 and A549 cells using confocal 
microscopy with DOX excitation at 488nm and signal collection between 530 and 688 
nm. 
Images were created using Fiji and using the z-projection (sum) along z-stacks taken 
with a Zeiss LSM 780 confocal microscope across entire cells. A Gaussian Blur filter 
with radius 0.3 μm was used to even the background. Brightness and contrast was ad-
justed for 1 h samples and kept identical for all images that were selected for the com-
parison. 
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Figure 24.  DOX emission signal in confocal z-stacks projections and taken 
from A549 cells incubated for 1 h, 2 h, 4 h and 6 h with 5µM 
DOX@DODAB:MO (1:2) and 5µM free DOX solutions. Grey arrows indicate 
the main differences described in the text. 
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Representative confocal microscopy results of A549 cells incubated with 
DOX@DODAB:MO (1:2) and free DOX solutions as selected from 8 measurements 
per fixed time point taken on two independently prepared cell samples are shown in 
Figures 24. 
Figure 24 (left) shows that after 1 h of incubation with DOX@DODAB:MO (1:2) inten-
sity can be observed inside the cells and high intensity in the nucleus and close around it 
localizing in intensity spots, indicating lysosomal accumulations (indicated with grey 
arrow and *). At 2 h and 4 h gradual increase of the intensity in nucleus and cytoplasm 
was observed, in addition some high intensity spots forming ´´clouds´´ (indicated with 
grey arrow and #) around the nucleus were noticed. After 6 h almost all intensity is in 
the nuclei, some high intensity spots remain inside the cytoplasm/lysosomes. Some cells 
have rounded up after longer exposure as can be seen from the transmission images 
(shown in Appendix D) and thus the intensity in those seems higher at chosen bright-
ness/contrast settings.  
For the interaction of free DOX solutions with A549 cells, some differences can be ob-
served in the time dependent uptake of the drug by cells (see Figure 24 right).  After 1 h 
of incubation with free DOX, a more homogenous DOX distribution is observed inside 
the cytoplasm and also intensity inside the nucleus can be observed. After 2 h the inten-
sity in nucleus and cytoplasm increased. After 4 h almost all DOX is inside the nucleus 
and after 6 h of exposure to free DOX solution some cells have high intensities in the 
nucleus but the majority of cells have decreased overall intensity in the nuclei while 
only some areas of nuclei have higher intensities. This phenomenon could be due to 
DOX intercalation with DNA, like the one that can be observed with e.g. Hoechst 
33342 nucleus stain at various cell cycle stages, when the chromosomes condensate. 
5.2.1.1 Cell line A-431 
Representative confocal microscopy results of A431 cells incubated with 
DOX@DODAB:MO (1:2) and free DOX solutions as selected from 8-10 measurements 
per fixed time point taken on two independently prepared cell samples are shown in 
Figure 25.  The transmission images are shown in Appendix D.  
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Figure 25. DOX emission signal in confocal z-stacks projections and taken 
from A431 cells incubated for 1 h, 2 h, 4 h and 6 h with 5µM 
DOX@DODAB:MO (1:2) and 5µM free DOX solutions. Grey arrows indicate 
the main differences described in the text. 
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A431 cells tend to grow in large groups and usually they are not forming one uniform 
layer but, in contrary, grow in some cases one on top of another. Because of that, some 
areas of the cell nuclei seem to have extremely high fluorescence intensity when the z-
projection along z-stacks was performed and adjusted brightness/contrast settings were 
applied. A Fiji macro was developed, that automatically adjusted colour scale settings 
for each image (Appendix D) and used for image processing for the confocal data taken 
of A431 cells incubated with free DOX. 
When A431 cells were incubated with DOX@DODAB:MO (Figure 25 left column) 
already after 1 h accumulation of DOX in the nucleus was visible, furthermore, DOX 
appears in intensity spots around the nucleus suggesting lysosomal colocalization (Fig-
ure 25, left column, indicated with grey arrow and *). DOX liposome uptake in this cell 
line occurs much faster than in the A549 cell line. After 2 h nuclei have high DOX in-
tensity with some high intensity spots close to the nucleus. After 4 h of incubation with 
the liposomes nuclei have high DOX intensity and homogeneous intensity is present 
also in cytoplasm. After 6 h intensity in nuclei and cytoplasm has increased even more.  
In addition, an interesting phenomenon was observed, when A431 cells were incubated 
with DOX@DODAB:MO – small intensity spots with high DOX intensities were ob-
served outside of cells and widely distributes across the cover slip surface (indicated 
with grey arrow and ~). These DOX emission spots were of small size (~10 µm) and the 
intensities increased for samples fixed at later time points. 
For samples exposed to free DOX (Figure 25, right column), homogeneous intensity 
inside the nucleus after 1 h was observed also there was presence of DOX in cytoplasm. 
After 2 h exposure to free DOX almost all DOX intensity is in nuclei, observed over-
lapping of the cells that might lead to higher intensity regions. After incubation of the 
cells with free DOX for 4 h and 6 h, DOX intensity has increased over time, almost no 
intensity is observed in the cytoplasm. 
5.2.2 Comparison of DOX@DODAB:MO versus Doxil® uptake 
Both cancer cell lines, A431 cells (epidermoid carcinoma) and A549 cells (lung carci-
noma), were exposed to the liposomal formulation DOX@DODAB:MO (1:2) and to 
commercial DOX - Doxil
®
 - solutions with overall comparable 40 µM DOX concentra-
tions. The samples were fixed after 1, 2, 4 and 6 hours of exposition to the DOX con-
taining liposomal solutions and DOX fluorescence intensity in confocal images was 
measured.  
Images were created using Fiji and using the z-projection along z-stacks taken with a 
Zeiss LSM 780 confocal microscope across entire cells. A Gaussian Blur filter with 
radius 0.3 μm was used to even the background. Brightness and contrast was adjusted 
for 1 h samples and kept identical for all images that were selected for the comparison. 
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5.2.2.1 Cell line A-549 
Representative confocal microscopy results of A549 cells incubated with 
DOX@DODAB:MO (1:2) and Doxil
® 
solutions and as selected from 8-10 measure-
ments per fixed time point taken on two independently prepared cell samples are shown 
in Figure 26. 
Figure 26 (left column) shows A549 cells exposed to DOX@DODAB:MO (1:2) lipo-
somal solutions. After 1 h high intensity in the nucleus can be observed and close 
around it DOX appears in intensity spots (indicated with grey arrow and *), in addition 
there is DOX intensity in cytoplasm. At 2 h and 4 h gradual increase of the intensity in 
nucleus and cytoplasm was observed. After 6 h almost all intensity is in nucleus and it is 
very high, some intensity spots remain inside the cytoplasm. The background intensity 
is low. Some cells have rounded up and some have distorted shapes after longer expo-
sure and thus the intensity in those seems higher at chosen brightness/contrast settings. 
The transmission images are shown in Appendix D. 
Figure 26 (right column) shows A549 cells exposed to Doxil
® 
solutions. After 1 h of 
incubation with Doxil
® 
more DOX distribution inside the cytoplasm and nucleus can be 
observed. The intensity in cytoplasm is rather homogeneous and only few localized in-
tensity spots around the nucleus are observed, which is distinct in the sample with 
DOX@DODAB:MO (1:2) (indicated with grey arrow and *). The homogenous inten-
sity may indicate a drug diffusion process through the cell membrane rather than an 
endocytosis uptake suggested for the liposomal uptake. After 2 h the intensity in nu-
cleus and cytoplasm increased, additionally there are some bigger high intensity spots 
near nuclei. After 4 h DOX is inside the nuclei and in cytoplasm. Some of the nuclei 
have reached high intensities and at given settings reached saturation. At 6 h time point 
all cells have high intensities in nucleus and saturation is observed. In addition, the in-
tensities in cytoplasm and background have increased. The background intensity is 
higher for samples with Doxil
® 
than with DOX@DODAB:MO. Some cells have 
rounded up as can be seen in transmission images (Appendix D) and some have dis-
torted shapes after longer exposure and thus the intensity in those seems higher at cho-
sen brightness/contrast settings. In addition, at 6 h cell debris can be observed in form of 
largely scattered DOX intensity spots that are visible as spots also in transmission im-
ages (Appendix D) and could be associated to cell death (indicated with grey arrow and 
~). 
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Figure 26. DOX emission signal in confocal z-stacks projections and taken 
from A549 cells incubated for 1 h, 2 h, 4 h and 6 h with 40µM 
DOX@DODAB:MO (1:2) and 40 µM Doxil® solutions. Grey arrows indicate the 
main differences described in the text. 
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5.2.2.2 Cell line A-431 
Representative confocal microscopy results of A431 cells incubated with 
DOX@DODAB:MO (1:2) and Doxil
® 
solutions and as selected from 8 to 10 measure-
ments per fixed time point taken on two independently prepared cell samples are shown 
in Figure 27.  The transmission images are shown in Appendix D.  
As observed in previous experiments with DOX@DODAB:MO (1:2) and free DOX, 
also in experiments with 40 µM DOX@DODAB:MO (1:2) and Doxil® A431 cells grew 
in large groups and were growing sometimes one on top of another. Because of that 
some areas of the cell nuclei seemed to have extremely high fluorescence intensity 
when the z-projection along z-stacks was performed and adjusted brightness/contrast 
settings were applied.  
In Figure 27 (left column) confocal images of A431 cells incubated with 
DOX@DODAB:MO are shown. After 1 h of incubation with DOX@DODAB:MO 
(1:2) some intensity spots indicating lysosomal accumulation of DOX (indicated with 
grey arrow and *), furthermore, DOX was present in the nucleus. DOX uptake in this 
cell line is very fast. After 2 h nuclei have increased DOX intensity with some high in-
tensity spots in the nucleus. After 4 h, nuclei have high DOX intensity and homogene-
ous intensity is present also in cytoplasm. After 6 h intensity in nuclei and cytoplasm 
has increased even more.  Once again, small aggregates across the coverslip and outside 
the cell areas were observed for A431 cells incubated with DOX@DODAB:MO.  These 
aggregates were small size (~10 µm) and the intensities increased over time. Less of 
these spots are observed in the cell samples exposed to Doxil
®
 liposomes only few of 
these intensity spots are visible in the 1h incubation image (Figure 27, right column). 
For samples exposed to Doxil
® 
high intensity inside the nucleus after 1 h was observed 
(Figure 27, right column), also there was presence of DOX in cytoplasm and some high 
intensity spots around nucleus. Overlapping of the cells might lead to higher intensity 
regions. After 2 h exposure to Doxil
® 
almost all DOX intensity is in nuclei. After 4 and 
6 h of incubation with Doxil
®
, DOX intensity has increased over time both in nuclei and 
in cytoplasm. 
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Figure 27. DOX emission signal in confocal z-stacks projections and taken 
from A431 cells incubated for 1 h, 2 h, 4 h and 6 h with 40µM 
DOX@DODAB:MO (1:2) and 40 µM Doxil® solutions. Grey arrows indicate the 
main differences described in the text. 
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5.2.3 Live cell studies on A431 live cells 
In experiments with fixed A431 cells, DOX accumulation in nuclei was observed al-
ready after 1 h of incubation. This caused curiosity to perform live A431 cell imaging 
and follow the cell uptake process with improved time resolution. Live A431 cells were 
incubated with 40 μM DOX@DODAB:MO and the nucleus was stained with Hoechst 
33342. Cells were imaged every 10 minutes and two colour z-stacks and transmission 
images were recorded simultaneously, starting from 30 min after exposure of the cells 
to the 40 μM DOX@DODAB:MO liposomal solution until 2 hours passed and cell 
death was observed (Figure 28). 
Images were processed using freeware Fiji. Figure 28 shows the z-projections along z-
stacks taken with a Zeiss LSM 780 confocal microscope across entire cells and trans-
mission image in focus. After 30 minutes DOX intensity was high around the nucleus 
and there seemed to be some intensity in nucleus. After 120 minutes DOX intensity was 
concentrated inside of the nucleus and the round shape of the cell indicates cell death. 
 
Figure 28. Merged confocal and transmission image taken of a live A431 cell 
with 40 μM DOX@DODAB:MO at time points 30 and 120 minutes after addi-
tion of DOX containing suspension. Grey: in-focus transmission images, red: 
DOX intensity z-projections along confocal z-stacks 
The acquired 3D video of a single cell allows following the liposomal uptake process in 
3D, with displayed nucleus, DOX intensity and overall shape (in transmission) seeing 
Figure 29. Figure 29 shows frames from such 3D video, where blue indicates the nu-
cleus stained with Hoechst 33342 and red corresponds to DOX intensity. At the 30 min 
time point DOX intensity is scattered around the nucleus and in cytoplasm. At later time 
points this intensity slowly increases and DOX “cloud” gets more concentrated. After 
90 min. formation of magenta colour can be observed thus assumption can be made that 
DOX has co-localized inside the nucleus. In next 30 minutes the DOX intensity in nu-
cleus increases.
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Figure 29. Time-dependent 3D confocal two colour images, as taken from a recorded 3D video of a single A431 cell exposed to 
DOX@DODAB:MO(1:2) liposomes and with the nucleus labelled with Hoechst 33342 , at 10 different time points (blue: Hoechst 33342 
emission, red: DOX emission). The arrows indicate the movement of recorded DOX fluorescence intensity.
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Figure 30. Time-dependent changes of an A431 live cell exposed to DOX@DODAB:MO suspension observed in transmission and con-
focal imaging modes. The images show an overlay of a single center slice of a z-stack together with an in focus transmission image at 10 
different time points after addition of the liposomal drug delivery system. Gray: in focus transmission images, Blue: Confocal image of 
the nucleus stained with Hoechst 33342, red confocal emission channel: DOX emission. The arrows indicate the movement of recorded 
DOX fluorescence intensity.
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Transverse slices through the cell center were taken from the 3D image data sets to ver-
ify that DOX has indeed accumulated inside the nucleus. In Figure 30 the in focus 
transmission image is visible in gray, blue is the nucleus stained with Hoechst 33342 
and red the DOX intensity. As the intensity of DOX was not z-projected it appears 
much lower. Nevertheless the same trend as in the 3D video was observed. DOX inten-
sity is clearly visible at 30 min time point around the nucleus and also in the cytoplasm. 
The DOX intensity distributions increase to later time points inside the overall cell and 
especially around and inside the nucleus. 
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6. DISCUSSION 
6.1 Liposomal characterization 
Smaller liposomes are better for intravenous drug delivery as these can reach longer 
circulation times. In agreement to this in the current work the main goal was to produce 
liposomal nanoparticles with controlled sizes preferably around 100 nm. The PdI value 
determined of fabricated liposomes with DLS is 0.161±0.01 and indicates that the lipo-
somal formulation is monodisperse. Liposome size distribution of 118.9±0.5 nm was 
successfully achieved.  High MO content in the formulation has the advantage of creat-
ing liposomal formulation with a mixture of lipid phases: DODAB forms a lamellar 
phase that encloses MO inverted non-lamellar phases. Based on literature review DO-
DAB:MO (1:2) liposomal system is able to encapsulate drugs, not only at the DODAB 
enriched bilayer level, but also at the inverted non-lamellar MO-enriched phases at the 
vesicle interior (da Rocha 2014). 
The surface charge of the nanoparticle is a good indicator about their shelf stability and 
efficiency to cross cell membranes. Liposomes with neutral charge are less stable and 
aggregate as there is no repulsion between the surface charge of the nanoparticles in 
suspension. Charged vesicles on the other hand have higher shelf stability due to the 
repulsion between the nanoparticles that keeps them in a stable suspension. Positively 
charged liposomes have the further advantage of facilitating the cellular adhesion as cell 
membranes are slightly negatively charged. Zeta potential of the DODAB:MO (1:2)  
liposomes is +50.4±9.5 mV, which means that they are stable and suited for cell adhe-
sion. 
The study of the nanoscale location of the drug in the liposome membrane plays crucial 
role in understanding drug-membrane interactions. For the DODAB:MO (1:2) lipo-
somal formulation fluorescence quenching studies demonstrated to be a suited proce-
dure. The quenching of the membrane-bound n-AS probes, which are characterized by 
the insertion of a reporter dye at different membrane depths, provide a measure of its 
accessibility to the quenching drug molecule. The molecular locations of the n-AS 
probe within the membrane are known and quenching studies can be used to find the 
location of quenchers inside the membrane. Four n-AS probes were used for nanoscale 
localization of DOX in DODAB:MO(1:2). 
The Stern–Volmer plots comparing the relative intensity change I0/I and the relative 
fluorescence lifetime change τ0/τ of the reporter dyes in dependence of the effective 
concentration of the quencher [Q]m were studied for all n-AS labelled DO-
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DAB:MO(1:2) liposomes encapsulating DOX at various concentrations (see Figure 21). 
Both, I0/I and τ0/τ against [Q]m curves were linear for all four n-AS probes. The slopes 
of these linear regressions correspond to the values of the Stern–Volmer constants of the 
quenching between the DOX and the n-AS probes (Table 4). The amount of dynamic 
quenching represented by the dynamic Stern–Volmer plot is smaller than the static 
quenching that is observed by steady-state fluorescence measurements at various DOX 
concentrations. Thus, it is concluded, that static quenching is the dominant quenching 
process.  
The bimolecular quenching rate constants were calculated for each n-AS sample to re-
move variances due to different native fluorescence lifetimes of the reporter dyes (dif-
ferent 0). The determined Kq values are small, and indicate that the fluorophores are 
rather immobilised in the lipid membrane as such values resemble those observed for 
macromolecules, rather than dye solutions (Lakowicz 2006a). The 9-AS probe has the 
strongest quenching as can be seen by the relative intensity and lifetime changes as 
function of [Q]m and therefore biggest Kq value, followed by 12-AS, 6-AS and 3-AS. It 
can be concluded that DOX locates relatively close to the bilayer centre being able to 
interact with all n-AS probes. 
When theoretically placing DOX and 9-AS molecules side-by-side with the polar group 
oriented to the polar portion of the bilayer and the aromatic portion aligned within the 
aliphatic tails, one can stipulate that methyl group of the DOX tetracycline ring is in 
proximate distance from polar 9-AS probe’s part, as shown in Figure 31. This could be the 
reason why the fluorescence intensity of 9-AS probe is quenched the most. 
 
Figure 31. Modelled DOX and 9-AS molecule orientation with respect to bi-
layer center. Created with software MarvinSketch 16.5.2 © 
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Another fluorescence based method particularly suited to measure the interaction of 
molecules in membranes is FRET. In this case, a direct transfer of energy from a fluo-
rescent donor (n-AS probe) to an acceptor (DOX) occurs if their inter-molecular dis-
tance is small (typically < 10 nm). Because of small distances required between donor 
and acceptor FRET, possesses the clear advantage of quantifying distances well below 
the optical resolution limit, thus enabling measuring distances at the molecular scale. 
FRET analysis results are summarized in Table 7. The shortest distance determined is 
24.8 Å between 9-AS and DOX molecules. Then 3-AS and 12-AS distances follow, the 
longest determined distance is between 6-AS and DOX molecules with 27.7 Å. 
6.2 In Vitro studies of cancer cell uptake 
The cellular uptake of a new liposomal formulation for DOX drug delivery was evalu-
ated in two cell lines: A431 and A549. Comparison was made between the 
DOX@DODAB:MO liposomes and free DOX and between DOX@DODAB:MO and 
commercial DOX liposomal formulation Doxil
®
. Each fixed cell experiment was re-
peated twice. 
Signatures of endosomal uptake are identified for both cell lines in form of intensity 
spots located around the nucleus for 5 μM and 40 μM DOX@DODAB:MO(1:2).  
While for the A431 cells nuclear internalization of 5 μM DOX@DODAB:MO(1:2) is 
already visible after 1 h, the A549 predominantly show intensity spots around the nu-
cleus at 1 h incubation time, while the nucleus is only reached at later time points, e. g.  
visible in the image taken after 6 h (Figure 24). Observations indicate that 5 μM 
DOX@DODAB:MO(1:2) leads to controlled release in time. The quicker DOX uptake 
in A431 cells could be due to EGF factor expression as reported in literature by Kwok 
& Sutherland (1991). 
Small high intensity spots observed across the cover slip in A431 cell preparations at 
late time points for both, low and high concentration DOX@DODAB:MO(1:2), could 
be explained as cell debris that remained after washing of cells. The positive surface 
charge of DODAB:MO(1:2) and slightly negative charge of cells attract and thus create 
these high intensity spots. 
With higher concentration of DOX in 40 μM DOX@DODAB:MO(1:2) liposomal for-
mulations, after 1 h incubation, DOX has already reached the nucleus of A549 cells 
(Figure 26). Whereas, in samples incubated with 5 μM DOX@DODAB:MO(1:2) after 1 
h only faint intensity of DOX can be observed (Figure 24). 
Free DOX reaches the cell nucleus in both cell lines already after 1 h; after 6 h in A549 
DOX signal is predominantly observed inside the nucleus (Figure 24). 
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Doxil
®
 shows faster uptake than for DOX@DODAB:MO(1:2) and slower than for free 
DOX in both cell lines. High intensity spots around nucleus are identified for both cell 
lines at early time points. At 6 h the intensity in nucleus for both cell lines is high. Fluo-
rescence intensity of DOX in A431 cells was overall higher than that in A549. This 
phenomenon could be due to “active loading” method used in encapsulation of DOX in 
Doxil
®
 to achieve high encapsulation efficiency. In this case it is possible that high 
number of free DOX is available in solution transported together with the liposomes and 
thus diffusion of DOX into cells can occur and uptake it faster. 
Live cell experiment of A431 cells taken with 10 min time resolution during 2 hours 
indicate that DODAB:MO(1:2) liposomal system enter the cells via the endocytosis 
pathway and subsequently release the DOX in controlled way (Figure 29). 
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7. CONCLUSIONS 
The thesis work aimed to employ the opportunity to experience the international re-
search environment in Portuguese university, University of Minho, and fully interna-
tional research organization, INL. It allowed to learn different research methods from 
renowned professionals and to conduct wide variety of experiments independently. A 
huge extent of thesis was achieved due to astonishing facilities available in INL and 
University of Minho. 
The objective of this thesis was to spectroscopically characterize pH-dependent lipo-
some formulation and, in addition, to characterize the internalization process of DOX-
loaded DODAB:MO (1:2) using advanced fluorescence imaging techniques. Successful 
experiments could support the potential as an anti-cancer drug delivery system of this 
novel liposomal formulation, as a controlled endosomal uptake of the liposomes is ob-
served. 
Different kinds of work methods were used in order to acquire the results of this thesis. 
After fabrication of the liposomes using the extrusion technique, cell culturing, cell 
fixation, and preparation for imaging and data analysis were performed. Additionally, 
experiments using optical spectroscopy methods using commercial devices, such as 
Malvern Zetasizer Nano ZS analyser, Horiba Scientific FluoroMax-4 spectrofluorome-
ter, Perkin Elmer Lambda 950 UV-VIS-NIR spectrometer, and ChronosBH, ISS fluo-
rescence lifetime spectrometer were used and advanced microscopy studies were per-
formed using a Zeiss LSM 780 confocal microscope. 
Based on DLS and ELS analysis the fabricated DODAB:MO (1:2) liposomal system 
can be considered stable and their small size suited to successfully employ EPR effect. 
For nanoscale localization of the DOX within the DODAB:MO(1:2) bilayer a fluores-
cence quenching assay with four n-AS probes was used. DOX@DODAB:MO(1:2) lo-
calizes buried at deeper locations inside the lipid bilayer leading to strongest quenching 
at the 9-AS probe that is attached to a C atom of the lipid chain 7.5 Å from the bilayer 
centre. The distance between 9-AS and DOX molecule is 24.8 Å as determined by a 
FRET assay. 
Confocal microscopy on fixed cells indicate that A431 and A549 cell lines use the en-
dosomal pathway for DOX@DODAB:MO(1:2) liposome uptake. A temporally phased 
uptake was observed when compared with commercially available liposomal solution 
Doxil® and free DOX. A431 cells uptake DOX faster than A549, live cell experiments 
64 
  
of A431 cells confirmed that DODAB:MO(1:2) liposomal system releases the DOX in 
controlled way. 
The location of the DOX towards the interior of the liposome could have interesting 
applications for drug delivery, and may be able to deliver more DOX at once without 
dimerization occurring. 
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8. OUTLOOK 
In the future, testing the DODAB:MO(1:2) liposomal system through more comprehen-
sive in vivo and 3D in vitro systems will allow the treatment system to be further devel-
oped, hopefully resulting in a new and better drug delivery systems on the market to 
help cancer patients. 
To develop a deeper understanding of the internalization and release mechanism rele-
vant, tissues shall be studied and thereby shall help to better identify the most suited 
nanocarrier candidates to advance towards the later stage of clinical trials. 
To advance efficiently the design process of novel nanotherapeutics, in future work I 
propose to use and develop a combination of spectroscopy and imaging techniques to 
follow the nanocarrier internalization and drug release. Identification of the differences 
in nanocarrier - cell interaction, e.g. when comparing cancer/non-cancer cells, drug re-
sistant/non-resistant cells and/or when comparing the effect of different commercially 
available and/or innovative potentially optimized nanoformulations with classical direct 
drug delivery shall be performed. 
By using in vitro cell assays, relevant basic interaction mechanisms between cells and 
nano drug carriers can be answered. Additionally, to reach more realistic prognosis of 
nanotherapy efficacy and targeted delivery in the human body, more realistic human 
tissue models based on the combination of various cancerous and non-cancerous in vitro 
engineered models and deep tissue imaging techniques are required to assess drug inter-
nalization, delivery and drug release. Ideally, biomimetic tissue model should simulate 
in vivo conditions to observe relevant release mechanisms. 
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APPENDIX A: MATLAB FITTING ALGORITHM 
Program 1. Matlab fitting algorithm 
%% Run fit_lsq 
  
clear x xdata ydata tau 
  
load('matlab.mat')    %structure containing data for all samples 
intensity1=str2double(tcspc(1, 8).Dataset(:,4,1)); %finding intensity values 
t_start=9.9;        %time interval start 
t_end=34;           %time interval end 
  
g=max(intensity1); 
[s1,s2]=find(intensity1 == g); %finding at which time point max peak occurs 
for time axis correction 
xdata=x-x(s1,1); 
i_start=interp1(x,1:length(x),t_start,'nearest'); 
i_end=interp1(x,1:length(x),t_end,'nearest'); 
xdata=xdata(i_start:i_end,1); 
xdata=xdata';                %finding the exact time vector 
  
tau=[1, 5, 0.1]; % Starting guess 
intensity = smooth(intensity1,9); 
ydata = intensity(i_start:i_end,1)./max(intensity); 
ydata =ydata'; 
  
 [F]= fit_lsq( xdata,ydata,tau )  %calling the least squares fitting function 
 F.fit=(F.b*exp(-(xdata)./F.tau1)+(1-F.b)*exp(-
(xdata)./F.tau2))*max(intensity); 
 F.chi=sum((F.fit-ydata).^2)./sum(ydata); 
 set(0,'defaultlinelinewidth',2) 
 figure;plot(xdata,F.fit,x-x(s1,1),intensity1) 
 legend('Fitted function','Measured data') 
 xlabel('t, ns', 'Fontsize', 14); 
 ylabel('Intensity', 'Rotation', 90, 'Fontsize', 14); 
 set(gca, 'XLim',[0,100]) 
Program 2. Matlab fitting function 
function F = fit_lsq( xdata,ydata,tau ) 
%fit_lsq function finds coefficients with best fit (with 0<b<1) 
%   xdata - time vector 
%   ydata - intensity vector 
%   tau - initial guess 
%   b - weighting factor of tau1 and tau2 (0<b<1) 
  
function [y_fit]= get_fitcurve_2c(tau,xdata) 
    tau1=tau(1); 
    tau2=tau(2); 
    b=tau(3); 
    y_fit=(b*exp(-(xdata)./tau1)+(1-b)*exp(-(xdata)./tau2)); % equation that 
has to be evaluated by lsqcurvefit 
  
end 
    fhandle = @get_fitcurve_2c; 
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    options = optimoptions('lsqcurvefit','MaxFunEvals',50000, 'MaxIter', 
50000);% optimization of options    
    [tau,resnorm] = lsqcurvefit(@get_fitcurve_2c,tau,xdata,ydata,[0 0 0],[inf 
inf 1],options) %starts at X0 and finds coefficients  
    F.tau1=tau(1); 
    F.tau2=tau(2); 
    F.b=tau(3); 
  
end 
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APPENDIX B: TCSPC MEASUREMENTS 
Table 1. Lifetime values,ns 
 Matlab ISS 
[DOX] 3AS_m 6AS_m 9AS_m 12AS_m 3AS_ISS 6AS_ISS 9AS_ISS 12AS_ISS 
0 6.903524 6.141001 7.333535 8.742043 7.596398 7.002174 9.034092 10.69319 
20 6.537212 5.874523 7.022964 8.609434 7.250448 6.958782 8.607769 10.58293 
40 6.789805 5.626665 6.920607 8.535996 7.563962 6.818364 8.431787 10.37803 
60 6.706415 5.745945 7.100697 8.517346 7.493347 6.783929 8.861613 10.614 
80 6.650808 5.649955 6.862521 8.467972 7.291034 6.798383 8.548535 10.6307 
100 6.481339 5.618484 6.718419 8.266475 7.32175 6.893652 8.542267 10.5186 
 
Table 2. χ2 values  
 Matlab ISS 
[DOX] 3AS_m 6AS_m 9AS_m 12AS_m 3AS_ISS 6AS_ISS 9AS_ISS 12AS_ISS 
0 1.04 1.02 1.06 1.04 1.03 1.00 1.00 0.99 
20 0.96 1.00 1.03 1.03 0.97 0.96 0.97 1.02 
40 1.01 1.06 1.03 1.02 0.98 1.03 0.98 1.00 
60 1.04 0.98 1.01 1.03 0.99 1.01 0.98 1.00 
80 0.99 1.06 1.06 1.02 1.00 1.01 1.03 1.01 
100 1.00 1.04 0.98 1.06 1.03 1.03 0.98 1.04 
 
 
 
 
 
 
 
 
 
 
73 
  
APPENDIX C: FLUORESCENCE EMISSION DATA SMOOTHING 
 
Figure 1. Example of recorded original steady state fluorescence emission data 
forDODAB:MO liposomes labelled with 6 AS probe and containing 20 μM of 
DOX (orange) and fitted smoothed data curve (blue) 
Due to spectrometer’s malfunction, in addition to the broad fluorescence spectrum nar-
row equidistant artefacts form part of the recorded spectra (Figure 1). The data curve 
was processed using Matlab function that smooths the response data ('rloess'). It assigns 
lower weight to outliers in the regression. Local regression using weighted linear least 
squares and a 2
nd
 degree polynomial model was used. Smoothed data sets were then 
background corrected by subtracting the minimum value from each measurement.  
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APPENDIX D: ABSORBANCE VALUES 
 
 
Figure 2. Absorbance values of the n-AS probes inserted in DODAB:MO liposomes 
determined at 385 nm as a function of DOX concentration. 
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APPENDIX D: CELL UPTAKE STUDIES 
Program 3. Fiji macro for increased brightness/contrast settings 
dir1 = getDirectory("Choose Source Directory "); 
dir2 = getDirectory("Choose Destination Directory "); 
list = getFileList(dir1); 
setBatchMode(true); 
for (i=0; i<list.length; i++)  
{showProgress(i+1, list.length); 
 open(dir1+list[i]); 
run("Split Channels"); 
close(); 
run("Z Project...", "projection=[Sum Slices]"); 
run("Gaussian Blur...", "sigma=0.30 scaled"); 
run("8-bit"); 
 
AUTO_THRESHOLD = 5000; 
 getRawStatistics(pixcount); 
 limit = pixcount/10; 
 threshold = pixcount/AUTO_THRESHOLD; 
 nBins = 256; 
 getHistogram(values, histA, nBins); 
 k = -1; 
 found = false; 
 do { 
         counts = histA[++k]; 
         if (counts > limit) counts = 0; 
         found = counts > threshold; 
 }while ((!found) && (k < histA.length-1)) 
 hmin = values[k]; 
  
 k = histA.length; 
 do { 
         counts = histA[--k]; 
         if (counts > limit) counts = 0;  
         found = counts > threshold; 
 } while ((!found) && (k > 0)) 
 hmax = values[k]; 
 
 setMinAndMax(hmin, hmax); 
run("yellowtored"); 
run("Invert LUT"); 
run("Calibration Bar...", "location=[Upper Left] fill=White label=Black num-
ber=3 decimal=0 font=12 zoom=1 overlay"); 
run("Scale Bar...", "width=100 height=4 font=14 color=Black background=None 
location=[Lower Right] bold"); 
saveAs("PNG", dir2+list[i]); 
 close(); 
} 
 
 
 
76 
  
 
Figure 3.  Transmission images of A549 cells incubated with DOX@DODAB:MO 
and free DOX 
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Figure 4. Transmission images of A431 cells incubated with DOX@DODAB:MO 
and free DOX 
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Figure 5. Transmission images of A549 cells incubated with DOX@DODAB:MO 
and  Doxil
®
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Figure 6. Transmission images of A431 cells incubated with DOX@DODAB:MO 
and Doxil
®
 
